

Report on the Burden of Endemic Health Care-Associated Infection Worldwide

Clean Care is Safer Care



WHO Library Cataloguing-in-Publication Data

Report on the burden of endemic health care-associated infection worldwide.

1.Cross infection - epidemiology. 2.Cost of illness. 3.Infection control. 4.Disease susceptibility. 5.Review literature. I.World Health Organization.

ISBN 978 92 4 150150 7

(NLM classification: WX 167)

© World Health Organization 2011

All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

The boundaries and names shown and the designations used on the maps do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

Printed by the WHO Document Production Services, Geneva, Switzerland

Report on the Burden of Endemic Health Care-Associated Infection Worldwide

A systematic review of the literature

CONTENTS

Acknowledgements	1
Abbreviations	2
Summary	3
Introduction	4
1. Health care-associated infections in different settings and related risk factors.	6
2. Methods and challenges of health care-associated infection surveillance	8
3. The burden of endemic health care-associated infection in high-income countries.	12
4. The burden of endemic health care-associated infection in low- and middle-income countries	16
5. The impact of health care-associated infection worldwide	20
6. Lessons learned and the way forward	22
References	26
Appendix	34

ACKNOWLEDGMENTS

Developed by the Clean Care is Safer Care Team (Patient Safety Programme - Innovation, Information, Evidence and Research Cluster).

Clean Care is Safer Care Team:

Benedetta Allegranzi, Sepideh Bagheri Nejad, Gabriela Garcia Castillejos, Claire Kilpatrick, Edward Kelley, Elizabeth Mathai.
External lead: Didier Pittet.

Content contribution

Lead author:

Benedetta Allegranzi
WHO Patient Safety Programme, Geneva, Switzerland

Critical technical contribution

Sepideh Bagheri Nejad
WHO Patient Safety Programme, Geneva, Switzerland
Didier Pittet
WHO Collaborating Centre on Patient Safety
University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland

Technical contribution

Marie-Noëlle Chraïti
WHO Collaborating Centre on Patient Safety
University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland

Statistical Analysis

Christophe Combescure
Division of Clinical Epidemiology
University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland
Homa Attar
WHO Collaborating Centre on Patient Safety
University of Geneva Hospitals and Faculty of Medicine, Geneva, Switzerland

Reviewers

Najeeb Al Shorbaji
WHO Patient Safety Programme, Geneva, Switzerland
Edward Kelley
WHO Patient Safety Programme, Geneva, Switzerland
Colin Mathers
WHO Mortality and Burden of Disease, Geneva, Switzerland

Editor

Rosemary Sudan
Freelance editor

Figures

Laurens Zwakhals
WHO Public Health Information and Geographic Information Systems, Geneva, Switzerland

ABBREVIATIONS

BSI	bloodstream infection
CDC	Centers for Disease Control and Prevention
CL	central line
CR-BSI*	catheter-related bloodstream infection
CR-UTI	catheter-related urinary tract infection
ECDC	European Centre for Disease Prevention and Control
EPIC	European Prevalence of Infection in Intensive Care
HAP	health care-associated pneumonia
HCAI	health care-associated infection
HELICS	Europe Link for Infection Control through Surveillance
HIV	human immunodeficiency virus
ICU	intensive care unit
INICC	International Nosocomial Infection Control Consortium
SSI	surgical site infection
NNIS	National Nosocomial Infection Surveillance System
NHSN	National Healthcare Safety Network
USA	United States of America
UTI	urinary tract infection
VAP	ventilator-associated pneumonia
WHO	World Health Organization

* CR-BSI is used as a generic term throughout the report when referring to different categories included in the retrieved articles, e.g. “central venous catheter-associated”, “central venous catheter-related”, “central line-associated”, or “catheter-related bloodstream infection”.

SUMMARY

Health care-associated infection (HCAI) is acquired by patients while receiving care and represents the most frequent adverse event. However, the global burden remains unknown because of the difficulty to gather reliable data. In many settings, from hospitals to ambulatory and long-term care, HCAI appears to be a hidden, cross-cutting problem that no institution or country can claim to have solved yet. HCAI surveillance is complex and requires the use of standardized criteria, availability of diagnostic facilities and expertise to conduct it and interpret the results. Surveillance systems for HCAI exist in several high-income countries but are virtually nonexistent in most low- and middle-income countries.

Data included in this report are the results of systematic reviews of the literature on endemic HCAI from 1995 to 2010 in high- and low/middle-income countries. According to published national or multicentre studies, pooled HCAI prevalence in mixed patient populations was 7.6% in high-income countries. The European Centre for Disease Prevention and Control (ECDC) estimated that 4 131 000 patients are affected by approximately 4 544 100 episodes of HCAI every year in Europe. The estimated HCAI incidence rate in the USA was 4.5% in 2002, corresponding to 9.3 infections per 1000 patient-days and 1.7 million affected patients.

The systematic review of the literature revealed clearly an extremely fragmented picture of the endemic burden of HCAI in the developing world. Only very scanty information was available from some regions and no data at all for several countries (66%). Many studies conducted in health-care settings with limited resources reported HCAI rates higher than in developed countries. Hospital-wide prevalence of HCAI varied from 5.7% to 19.1% with a pooled prevalence of 10.1%. Of note, the pooled HCAI prevalence was significantly higher in high- than in low-quality studies (15.5% vs 8.5%, respectively). Surgical site infection (SSI) is the most surveyed and most frequent type of infection in low- and middle-income countries with incidence rates ranging from 1.2 to 23.6 per 100 surgical procedures and a pooled incidence of 11.8%. By contrast, SSI rates vary between 1.2% and 5.2% in developed countries.

The risk of acquiring HCAI is significantly higher in intensive care units (ICUs), with approximately 30% of patients affected by at least one episode of HCAI with substantial associated morbidity and mortality. Pooled cumulative incidence density was 17.0 episodes per 1000 patient-days in adult high-risk patients in industrialized countries. By contrast, the incidence of ICU-acquired infection among adult patients in low- and middle-income countries ranged from 4.4% up to 88.9% and pooled cumulative incidence density was 42.7 episodes per 1000 patient-days.

High frequency of infection is associated with the use of invasive devices, in particular central lines, urinary catheters, and ventilators.

Among adult ICU patients in high-income countries, pooled cumulative incidence densities of catheter-related BSI (CR-BSI), urinary catheter-related UTI (CR-UTI), and ventilator-associated pneumonia (VAP) were 3.5 per 1000 CL-days, 4.1 per 1000 urinary catheter-days, and 7.9 per 1000 ventilator-days, respectively. In low- and middle-income countries, pooled cumulative incidence densities of CR-BSI, CR-UTI, and VAP were 12.2 per 1000 CL-days, 8.8 per 1000 urinary catheter-days, and 23.9 per 1000 ventilator-days, respectively. Newborns are also a high-risk population in developing countries and neonatal infection rates are three to 20 times higher than in industrialized countries.

The impact of HCAI implies prolonged hospital stay, long-term disability, increased resistance of microorganisms to antimicrobials, a massive additional financial burden for health systems, high costs for patients and their families, and excess deaths. In Europe, HCAIs cause 16 million extra-days of hospital stay, 37 000 attributable deaths, and contribute to an additional 110 000 every year. Annual financial losses are estimated at approximately € 7 billion, including direct costs only. In the USA, approximately 99 000 deaths were attributed to HCAI in 2002 and the annual economic impact was estimated at approximately US\$ 6.5 billion in 2004. Information is again very scanty from low- and middle-income countries and no data are available at national or regional levels. According to a report on device-associated infections in 173 ICUs from 25 countries in Latin America, Asia, Africa, and Europe, crude excess mortality in adult patients was 18.5%, 23.6%, and 29.3% for CR-UTI, CR-BSI, and VAP, respectively. A review of several studies showed that increased length of stay associated with HCAI varied between 5 and 29.5 days.

Although HCAI global estimates are not yet available, by integrating data from published studies, there is clear evidence that hundreds of millions of patients are affected every year worldwide, with the burden of disease much higher in low- and middle-income countries. There is an urgent need to establish reliable systems for HCAI surveillance and to gather data on the actual burden on a regular basis. Evaluation of the key determinants of HCAI is an essential step to identify strategies and measures for improvement. Robust evidence exists that HCAI can be prevented and the burden reduced by as much as 50% or more. Solid recommendations have been issued by national and international organizations, but their application needs to be strengthened and accompanied by performance monitoring both in high-income and low- and middle-income countries. HCAI must be treated as a priority patient safety issue within comprehensive approaches to be tackled effectively. The WHO Patient Safety programme integrates efforts with other WHO programmes to reduce HCAI by assisting with the assessment, planning, and implementation of infection prevention and control policies, including timely actions at national and institutional levels.

INTRODUCTION

Health care-associated infections (HCAIs) are infections that patients acquire while receiving treatment for medical or surgical conditions and are the most frequent adverse event during care delivery.¹ HCAI is a major problem for patient safety and its impact can result in prolonged hospital stay, long-term disability, increased resistance of microorganisms to antimicrobial agents, a massive additional financial burden for the health system, high costs for patients and their families, and excess deaths.^{2,3} The risk to acquire HCAI is universal and pervades every health-care facility and system worldwide, but the true burden remains unknown in many nations, particularly in developing countries.

Data on the burden of diseases worldwide are regularly published by the World Health Organization (WHO) to inform health-care workers, policy-makers, and the public of the most important diseases in terms of morbidity and mortality.⁴ HCAI does not appear on the list of over 100 diseases evaluated. The most likely reason is that the diagnosis of HCAI is complex and relies on multiple criteria and not on a single laboratory test. In addition, national systems of continuous surveillance are seldom in place. In many settings, from hospitals to ambulatory and long-term care, HCAI appears to be a hidden, cross-cutting problem that no institution or country can claim to have solved yet.

This report presents the evidence available from the scientific literature on the endemic burden of the most frequent types of HCAI and provides an assessment of epidemiological differences among countries according to income levels. The report aims also to identify major obstacles and gaps to assess the magnitude of the HCAI burden worldwide and to identify solutions and future perspectives for improvement. All data presented were compiled from systematic reviews of studies published in the scientific literature from 1995 to 2010. Methods and key definitions used are described in Boxes 1 and 2.



© University of Geneva Hospitals

Box 1

Methodology used for systematic reviews and analysis included in this report

Type of infection

Overall HCAI, health care-associated urinary tract infection (UTI), surgical site infection (SSI), hospital-acquired pneumonia (HAP), ventilator-associated infection (VAP), and health care-associated bloodstream infection (BSI).

Sources

PubMed, Cochrane Library, World Health Organization (WHO) regional medical databases (Appendix). A comprehensive list of search terms (Appendix) including MeSH terms “cross infection”, “infection control”, “developing countries” and “developed countries” was used, together with the individual names of high-, middle- and low-income countries.

Inclusion criteria

All studies reporting full or partial data related to infection rates, risk factors, mortality, excess length of stay, costs, HCAI aetiology in general, and health care-associated UTI, BSI, SSI, and HAP/VAP. For high-income countries, only national or multicentre studies were included.

Exclusion criteria

Duplicate references and publications reporting the same data; studies reporting outbreaks; studies including community-acquired infections.

Time limits

January 1995 to December 2010.

Language

No language restrictions.

Criteria to define high-quality studies

prospective design; use of standardized definitions (i.e. according to the USA CDC NHSN system);⁵ detection of at least all four major infections for studies related to HCAI in general; and publication in a peer-reviewed journal.

Statistical analysis

Descriptive statistics of data retrieved from high, low- and middle-income countries were performed; studies were classified according to patient population (adult, neonatal and paediatric), level of risk (high-risk patients, i.e. those admitted to ICUs, burn and transplant recipients vs mixed patient populations, including patients admitted to other lower-risk areas), and type of infection (overall HCAI, including at least the four most frequent infections, UTI, SSI, BSI, and HAP/VAP). Data pooling was performed by using meta-analytical techniques.

Box 2

Epidemiological definitions used in this report

HCAI prevalence

Number of infection episodes or infected patients per 100 patients present in the health-care setting or ward at a given point in time.

HCAI incidence

Number of new infection episodes or new patients acquiring an infection per 100 patients followed up for a defined time period. Periods vary according to the patient population. For SSI, it is usually 30 days after surgery (1 year in the case of prosthesis or implant), whereas it refers to the duration of hospital or ward stay for other infections.

HCAI incidence density

Number of infection episodes per 1000 patient-days or device-days.

Developed countries

High-income countries according to the World Bank classification 2009.⁶

Developing countries

Low- and middle-income countries according to the World Bank classification 2009.⁶



© WHO



© WHO

1.

Health care-associated infection in different settings and risk factors

HCAI is defined as: “An infection occurring in a patient during the process of care in a hospital or other health-care facility which was not present or incubating at the time of admission. This includes infections acquired in the hospital, but appearing after discharge, and also occupational infections among staff of the facility”.⁷ Given this definition and before focusing on epidemiological data, it is important to scrutinize the issue of HCAI in depth, to identify how it can be related to different types of health-care settings, and to determine the factors leading to an increased risk of transmission of health care-associated pathogens and of infection onset.


Most studies reporting data on the burden of endemic HCAI were conducted in acute-care settings and in high-income countries. However, an increasing body of evidence has highlighted the epidemiological differences in non-acute care settings and in low- and middle-income countries. The modern evidence-based approach to infection prevention and control clearly emphasizes that no type of health-care facility in any country can claim to be free from the risk of HCAI.

The term “HCAI” has replaced the former ones used to refer to such infections, i.e. “nosocomial” or “hospital” infection, as evidence has shown that this event can affect patients in any settings where they receive care. Only scanty data exist on the burden of HCAI outside hospitals because the culture of infection prevention and control and the systems for the surveillance of these events are inexistent or poorly developed in these settings. For instance, many patients probably acquire respiratory infections while seeking care for other diseases and waiting in ambulatory care facilities, especially in overcrowded settings in developing countries, or during epidemic periods. As the patient returns to the community, it is almost impossible to identify the occurrence of an infection acquired while accessing a primary care facility. Although no systematic data are available on the epidemiology of HCAI in primary and secondary care, the need for a targeted approach to infection control in these settings has been highlighted⁸ and specific recommendations have been issued in some countries, e.g. in England.⁹ Home care has also become highly prevalent. For example, in 1996 in the USA, 8 million patients received care at home; of these, 774 113 had at least one indwelling medical device, mostly intravascular.¹⁰ HCAI is no longer restricted to basic hospital care as in the past and now requires the implementation of specific infection control measures in other settings.

Due to longer life expectancy and social dynamics, an increasing number of individuals in high-income countries are nursed in residential homes for the elderly, but little is known about the burden of HCAI in these settings. Several projects on infection control in long-term care facilities have been initiated in Europe over the last five years.¹¹ Accumulated evidence suggests that any



© University of Geneva Hospitals



© WHO



© WHO

resident living in these facilities develops one to three infections per year on average, most frequently urinary tract infection (UTI) and pneumonia. It was also demonstrated that the onset of infection represents the most common cause of hospital admission and death for residents in long-term care facilities, mainly from pneumonia.^{12,13}

two or more underlying diseases.¹⁹⁻²⁸ Although not demonstrated as independent risk factors, general barriers to optimal infection control practices in low- and middle-income countries are lack of financial support, inadequate numbers of trained personnel working in infection control, understaffed hospital units, and insufficient equipment and supplies.³

Risk factors for HCAI vary according to the type of health-care facility and to the care area where the patient is admitted, and are partially different in developing countries. In studies conducted hospital-wide in high-income countries, the most common factors independently associated with HCAI occurrence were: age >65 years; admission as an emergency and to the intensive care unit (ICU); hospital stay longer than seven days; placement of a central venous catheter, indwelling urinary catheter, or an endotracheal tube; undergoing surgery; trauma-induced immunosuppression; neutropenia; a rapidly or ultimately fatal disease (according to the McCabe-Jackson classification); and impaired functional or coma status.¹⁴⁻¹⁸ The same risk factors were identified in acute-care settings in low- and middle-income countries with the addition of other determinants that are more broadly associated with poverty, such as a lack of basic hygiene and limited resources. These include malnutrition, age < 1 year, low birth weight, parenteral nutrition, or



© WHO

2.

Methods and challenges of health care-associated infection surveillance

Most HCAs become evident 48 hours or more following admission (typical incubation period).⁵ Infection may present also after patient discharge. In these cases, the patient has become colonized or infected while in hospital, but the pathogen incubation period exceeds the patient's hospital stay. For instance, several studies report that over 50% of surgical site infections (SSI) manifest post-discharge.²⁹⁻³⁸

HCAI may be caused by infectious agents from endogenous or exogenous sources. Endogenous sources are body sites, such as the skin, nose, mouth, gastrointestinal tract, or vagina, that are normally colonized by local microbial flora. These microorganisms can become invasive under certain favourable conditions and/or cause infection when they contaminate sterile sites. Transmission to these sites occurs most frequently via health-care workers' hands.³⁹ Exogenous sources are those external to the patient, such

as health-care workers, visitors, patient care equipment, medical devices, or the health-care environment. HCAs are not restricted only to patients; health-care workers, ancillary staff, and visitors can also be affected.

HCAs occur both as part of an endemic (ongoing) trend within a health-care facility or as epidemic situations, i.e. when new cases in a given population and during a given period substantially exceed what is expected, based on local endemic data. The endemic situation and occurrence of outbreaks in a health-care setting are important indicators of the quality and safety of patient care. For this reason, surveillance is at the heart of infection prevention and control. Surveillance is defined as "the ongoing, systematic collection, analysis, and interpretation of health data essential to the planning, implementation and evaluation of public health practice, closely integrated with the timely dissemination of these



data to those who need to know".⁴⁰ Surveillance activities are an essential tool to reduce HCAI as they are the important first step in identifying problems and priorities. Furthermore, it has been shown that conducting prospective surveillance activities, especially if prolonged, help to raise awareness of the problem and, finally, to decrease infection rates.⁴¹⁻⁴³

The use of standardized definitions is crucial to the reliability of HCAI surveillance. These allow to establish that the infection was acquired during hospital stay, to ascertain that the condition is a true infection and not a colonization (i.e. the presence of microorganisms on skin or mucous membranes, in open wounds, or in excretions/secretions, but without any overt adverse clinical signs or symptoms) or contamination (i.e. the exceptional and accidental presence of microorganisms in normally sterile body sites or fluids that does not reflect actual infection status), and to define the type of infection according to the body site. The most reliable definitions are those issued by the USA National Nosocomial Infections Surveillance (NNIS) system and recently revised by the National Healthcare Safety Network (NHSN)⁵. The application of standardized definitions is one of the minimum requirements for data comparisons at local, national, and international levels, although other variables need to be taken into account to allow appropriate benchmarking.



The use of these definitions requires the evaluation of clinical evidence collected from a review of the patient chart or other clinical records and/or the performance of microbiologic tests and/or direct observation of the infection site, e.g. surgical wound, catheter insertion site, etc.⁵ Further evaluation of diagnostic investigations or clinical information by a physician or a surgeon may be necessary (e.g. direct observation during a surgical operation, endoscopic examination) for the application of some criteria defining HCAI. These requirements lead to an accurate diagnosis in most cases, but make surveillance a resource-demanding activity. In settings where electronic patient records and automated systems exist, combining this information with the use of specific software or databases greatly simplifies HCAI surveillance. In settings with limited resources,

these systems are usually lacking, medical and nurse records are often not well organized and detailed, and access to laboratory and radiological facilities is very limited and frequently of low quality. In addition, in low- and middle-income countries, a lack of expertise in the field of infection prevention and control, understaffing, overcrowding, and limited financial resources constitute real constraints to HCAI surveillance performance.

HCAI surveillance is a challenging task also because it requires a particular expertise after obtaining epidemiological data to assess the quality of the information produced, and to interpret its meaning and root cause in order to tailor intervention and prevention measures. The establishment and maintenance of surveillance encompasses various steps including specific components (Table 2.1).

Table 2.1
Main steps and components of a HCAI surveillance system

Surveillance steps	Components
1. Planning	<ul style="list-style-type: none"> Assessment of available expertise, facilities and resources. Identification of specific objectives, scope, and methods, according to the local reality. Selection of standardized definitions and preparation of surveillance protocols.
2. Implementation	<ul style="list-style-type: none"> Clinical data collection and other investigations conducted. Completion and finalization of data collection forms. Ongoing laboratory surveillance of sentinel microorganisms.
3. Analysis and feedback	<ul style="list-style-type: none"> Data analysis and interpretation. Local feedback adapted to the most appropriate means.
4. Interventions driven by surveillance	<ul style="list-style-type: none"> Identification of appropriate and feasible interventions and priority areas according to specific results of surveillance. Repetition of surveillance activities to assess the impact of interventions and their adjustment according to results.

Surveillance can be passive or active, prospective or retrospective. Passive surveillance is the most common form of surveillance and relies on data routinely generated from automated patient records, e.g. laboratory-based surveillance and data extraction from patient records after discharge. It has typically a low sensitivity and may lead to misclassification and underreporting because the criteria for diagnosis may be not easily available. However, passive surveillance is less demanding and may be the only feasible method in settings

lacking expertise and resources for active surveillance. Conversely, active surveillance should be conducted by trained personnel, usually infection control professionals, who look for evidence to meet standardized diagnostic criteria of HCAI by using a variety of data sources. Active surveillance has higher specificity and sensitivity than passive surveillance and should be preferred if resources permit.

Prospective surveillance monitors pre-selected indicators in hospitalized patients, according to a specific protocol. In some cases, it may be extended to the post-discharge period; this is particularly important for SSI.^{29-38,44,45} Retrospective surveillance relies on previously-recorded routine data after patient discharge and, thus, relevant information may be lacking and some diagnostic criteria not fulfilled. Prospective surveillance is considered the gold standard for the collection of reliable and timely information, particularly in areas housing high-risk patients, and its inherent active nature strengthens the link to related interventions. However, it is more resource-expensive and time-consuming than retrospective surveillance.

The clinical history and diagnosis of a HCAI case is given below to illustrate its complexity, the diagnostic implications, and the consequences of this complication at all levels in a patient seeking care for different underlying diseases (A HCAI case: diagnosis and clinical situation).



© WHO

A HCAI case: diagnosis and clinical situation

In July 2009, a 46-year-old woman was admitted to a university hospital for further investigation of chronic eczema that had not responded to several treatment regimens with oral corticosteroids and topical medication.

On admission, the patient was found to be colonized with methicillin-resistant *Staphylococcus aureus* (MRSA) and received de-colonization treatment with chlorhexidine and nasal mupirocin. A chest X-ray, performed because of persistent cough, revealed lung cancer. She was transferred to the oncology unit and surgical removal of the lesion was planned after three cycles of neo-adjuvant chemotherapy. The first cycle was administered without any major complication. A port-a-catheter (PAC) was inserted via the jugular vein under antibiotic prophylaxis (cefuroxime). Swab cultures of the nose performed after de-colonization treatment remained positive for MRSA. The patient was discharged in good condition under treatment with oral dexamethasone and topical medication for her dermatitis, and with the PAC in place while waiting for her second chemotherapy cycle.

Ten days later, the patient was admitted to the emergency unit of a peripheral hospital for fever, severe hypotension, and leucocytosis. Pus secretions were observed on the PAC insertion site wound. Staphylococci were detected in secretions by microscopy and 24 hours later the blood cultures performed at admission grew MRSA. Intravenous antibiotic treatment with vancomycin was started and the patient was transferred to the university hospital where the catheter was removed and a drain was put in place. Culture of the catheter tip was performed and yielded MRSA.

A few days later, the patient developed neck oedema and septic thrombosis of the left internal jugular, subclavian, and axillary veins was diagnosed. Intravenous rifampin was added to the previous antibiotic therapy and a trans-oesophageal echocardiography was performed to exclude endocarditis. The examination proved negative. After three weeks of antibiotic therapy, the patient developed vaginal candidiasis that was treated with topical antifungal drugs.

The patient's condition slowly improved after an overall four-week intravenous antibiotic treatment course. Once recovered from the infection, the patient underwent her second chemotherapy cycle and was subsequently treated with radiotherapy and surgery.

Source: University of Geneva Hospitals, Geneva, Switzerland

Why is this a case of HCAI?

The patient was at risk because she probably developed immunosuppression due to long-term corticosteroid treatment. She was found to be colonized by MRSA and underwent standard topical eradication treatment, but she remained positive at first follow-up. She subsequently developed signs of infection following insertion of PAC: fever $>38^{\circ}\text{C}$; inflammatory syndrome; and signs of a localized infection (purulent discharge of the catheter insertion site).

The following criteria indicated that the patient developed a deep surgical site infection associated with catheter-related bacteraemia:

- an infection occurring 30 days following a surgical procedure;
- purulent discharge at the PAC insertion site;
- deliberate opening of the PAC insertion site and PAC removal by the surgeon;
- positivity of the purulent secretions, blood cultures and catheter tip for the same microorganism (MRSA).

As a consequence of this complication:

- extensive vascular complications occurred (septic thrombosis of jugular, subclavian, and axillary veins);
- an invasive diagnostic procedure was performed to exclude endocarditis (trans-oesophageal echocardiography);
- an additional surgical intervention was required to remove the PAC;
- there was a need for long-term antibiotic treatment;
- multiple peripheral venous lines and one central venous line were inserted for supportive and antibiotic therapy;
- vaginal mycosis occurred due to prolonged antibiotic therapy;
- there was a delay in the treatment of the pulmonary cancer;
- the patient (mother of three children) was hospitalized and away from home for 35 days.



3.

The burden of endemic health care-associated infection in high-income countries

National HCAI surveillance systems exist in several high-income countries and data are usually available through national reports and/or nationwide, or multicentre studies published in the scientific literature (Figure 3.1). According to our review, 131 national or multicentre studies conducted in 23 high-income countries were published from 1995 to 2010. The European Centre for Disease Prevention and Control (ECDC) reported that 13/28 (46.4%) European high-income countries had national surveillance systems in place in 2008 to monitor either ICU-acquired infections, SSI, or both, and were regularly reporting to the Hospitals in Europe Link for Infection Control through Surveillance (HELICS) network.⁴⁶ In the USA, more than 3000 health-care facilities regularly report data on ICU-acquired infections to the NHSN (<http://www.cdc.gov/nhsn/>), established by the Centers for Disease Control and Prevention (CDC). Other high-income countries, such as Australia, France,

Germany, and Japan, have coordinated surveillance at national or state level. Our literature review on high-income countries identified 55 studies with a national scope, mostly conducted in countries with a national surveillance system in place.

In national and multicentre studies identified, the prevalence of hospitalized patients who acquired at least one HCAI ranged from 3.5%⁴⁷ to 12%⁴⁸ (Figure 3.2). Pooled HCAI prevalence obtained through meta-analysis from studies conducted in mixed patient populations was 7.6 episodes per 100 patients (95% CI 6.9-8.5) and 7.1 affected patients per 100 patients (95% CI 6.5-7.8).^{14-18,47-75} HCAI prevalence figures reported in the most recent studies available from high-income countries are shown in Figure 3.3.

Figure 3.1
Number of national and multicentre studies reporting health care-associated infection in high-income countries, 1995-2010




Figure 3.2

Health care-associated infection prevalence in high-income countries versus low- and middle-income countries, 1995-2010





Figure 3.3

Prevalence of health care-associated infection in high-income countries, 1995-2010*




* For countries with more than one study, the most recent figures are included.

The ECDC reported that approximately 4 131 000 patients are affected by about 4 544 100 episodes of HCAI every year in Europe, with a mean HCAI prevalence of 7.1%.⁷⁶ The estimated HCAI incidence rate in the USA was 4.5% in 2002, corresponding to 9.3 infections per 1000 patient-days and 1.7 million affected patients.⁷⁷ In the USA and Europe, UTI was the most frequent type of infection hospital-wide (36% and 27%, respectively).^{76,77} In the USA, this was followed by SSI (20%), bloodstream infection (BSI), and pneumonia (both 11%).⁷⁷ In Europe, the second most frequent type was lower respiratory tract infection (24%), followed by SSI (17%), and BSI (10.5%).⁷⁶ According to several studies, the frequency of SSI varies between 1.2% and 5.2% in high-income countries.^{43,44,77-88}

The HCAI burden is much more severe in high-risk populations, such as patients admitted to ICUs, burn and transplant patients, and neonates. According to a recent European multicentre study, the proportion of infected patients in the ICU can be as high as 51%; most of these are health care-associated.⁸⁹ In high-income countries, approximately 30% of ICU patients are affected by at least one episode of HCAI with substantial associated morbidity and mortality.⁹⁰ Based on large studies from USA and Europe included in our review, HCAI incidence density ranged from 13.0 to 20.3 episodes per 1000 patient-days (Figure 3.4) and pooled cumulative incidence was 17.0 episodes per 1000 patient-days in adult high-risk patients in industrialized countries (Table 3.1 and Figure 3.4).^{77,91-94} High frequency of infection is associated with the use of invasive devices, in particular central lines, urinary catheters, and ventilators. In a report from the USA NNIS system, 83% of episodes of hospital-acquired pneumonia were associated with mechanical ventilation, 97% of UTIs occurred in catheterized patients, and 87% of primary BSI in patients with a central line.⁹³ Among adult ICU patients in high-income countries, pooled cumulative incidence densities of catheter-related BSI (CR-BSI), urinary catheter-related UTI (CR-UTI), and ventilator-associated pneumonia (VAP) were 3.5 (95% CI 2.8-4.1) per 1000 CL-days,⁹⁵⁻¹¹⁰ 4.1 (95% CI 3.7-4.6) per 1000 urinary catheter-days,⁹⁸⁻¹¹⁰ and 7.9 (95% CI 5.7-10.1) per 1000 ventilator-days,⁹⁸⁻¹¹¹ respectively (Table 3.1 and Figure 3.4). Comparisons with data available from the NHSN system¹⁰⁹ and the German hospital infection surveillance system (Krankenhaus Infektions Surveillance System [KISS])¹¹²

- 13/28 (46.4%) European high-income countries reporting either ICU-acquired infections, SSI, or both, to the HELICS network in 2008.
- HCAI pooled prevalence in mixed patient populations in high-income countries: 7.6%.
- More than 4 million patients affected by HCAI every year in Europe; 1.7 million affected patients in USA.
- Frequency of SSI varies between 1.5% and 5.2% in high-income countries.
- In high-income countries, approximately 30% of ICU patients are affected by at least one episode of HCAI.

Figure 3.4
Incidence of overall health care-associated infection and device-associated infection in high-risk adult patients in high-income countries, 1995-2010



highlight that these pooled values are similar, although slightly higher. On average, VAP is the most frequent type of infection in the ICU (32%), followed by CR-UTI and CR-BSI (both 20%), according to studies included in our review.^{91-96,98-111,113-118}

Very low birth weight (<1500g) neonates requiring intensive care are a population at high risk for HCAI. Data from recent multicentre studies conducted in Canada and Germany reported that 23.5% and 12.3% of patients are affected, respectively.^{119,120} Lower HCAI rates are reported in paediatric ICUs. For instance, in the USA, HCAI incidence in this patient population was reported to be 5.7%.¹²¹ Device-associated infection densities were 1.8 episodes per 1000 ventilator-days, 3 episodes per 1000 CL-days, and 4.2 episodes per 1000 urinary catheter-days, for VAP, CR-BSI, and CR-UTI, respectively.¹⁰⁹

In large studies conducted in France, Germany, and Italy included in our review, of 13 954 isolates, the most frequently reported pathogens in ICU-acquired infections were: *Staphylococcus aureus* (21.8%); enterobacteriaceae (20.2%); *Pseudomonas* spp. (17.2%); enterococci (10.0%); *Escherichia coli* (9.1%); *Candida* spp. (8.8%); coagulase-negative staphylococci (7.0%); and *Acinetobacter* spp. (5.1%).^{92,115,122,123} These microbiological patterns were similar to those reported in 1995 by the European Prevalence of Infection in Intensive Care (EPIC) study,¹²⁴ apart from coagulase-negative staphylococci, which were more commonly observed. Among 42 247 isolates from different studies included

in our review,^{16-18,48,51,56,57,62,65,66,71,125} *E. coli* (20.1%) and *S. aureus* (17.8%) were the most frequent single pathogens causing HCAI in mixed patient populations, thus reflecting the fact that UTI and SSI are the most common types of infection encountered. Other key pathogens were: *Pseudomonas* spp. (11.5%), enterobacteriaceae (10.6%); *Candida* spp. (6.7%); enterococci (6.5%); *Acinetobacter* spp. (5.8%); and coagulase-negative staphylococci (5.3%).

Table 3.1

Pooled cumulative incidence density of HCAI and device-associated infection in adult ICU patients in high-, middle- and low-income countries.

Surveillance networks/reviews, study period, country	HCAI/ 1000 patient-days (95% CI)	Patient days	CR-BSI/ 1000 central line days (95% CI)	Catheter-days	CR-UTI/ 1000 urinary catheter days (95% CI)	Urinary catheter-days	VAP/ 1000 ventilator days (95% CI)	Ventilator-days
NHSN, 2006–2008, USA# ¹⁰⁹	/	/	2.1	699 300	3.4	546 824	2.9	383 068
KISS, 2004-2009, Germany ¹¹²	/	/	1.3	4 002 108	2.0	4 757 133	5.1	2 391 381
Systematic review, high-income countries 1995-2010*	17.0 (14.2-19.8)	32 537 324	3.5 (2.8-4.1)	5 339 322	4.1 (3.7-4.6)	13 614 567	7.9 (5.7-10.1)	5 339 322
INICC, 2003–2008, 25 developing countries† ¹⁵⁸	/	/	7.4	362 882	6.1	403 545	14.7	275 111
Systematic review, low- and middle-income countries (1995-2010)*	42.7 (34.8-50.5)	193 139	12.2 (10.5-13.9)	891 220	8.8 (7.4-10.3)	970 710	23.9 (20.7-27.1)	679 950

HCAI = health care-associated infection; CR-BSI = catheter-related bloodstream infection; CR-UTI = catheter-related urinary tract infection; VAP = ventilator-associated pneumonia; NHSN = National Healthcare Safety Network; KISS=Krankenhaus Infektions Surveillance System; INICC=International Nosocomial Infection Control Consortium.

Medical/surgical ICUs in major teaching hospitals

* Specific references can be found in the text

† Argentina, Brazil, China, Colombia, Costa Rica, Cuba, Greece, India, Jordan, Kosovo, Lebanon, Lithuania, Macedonia, Mexico, Morocco, Pakistan, Panama, Peru, Philippines, Salvador, Thailand, Tunisia, Turkey, Venezuela, Vietnam

4.


The burden of endemic health care-associated infection in low- and middle-income countries

While HCAI surveillance systems are in place at national/sub-national level in many developed countries, only 23 developing countries (23/147 [15.6%]) reported a functioning national surveillance system, according to a survey conducted by the WHO First Global Patient Safety Challenge (*Clean Care is Safer Care*; <http://www.who.int/gpsc/en/>) in 2010. As highlighted in section 2, HCAI surveillance is a highly demanding and challenging task and settings with limited resources experience many constraints to evaluate the burden of HCAI. In low- and middle-income countries, regular monitoring of HCAI occurrence may be unfeasible at national level and, thus, Ministries of Health are unable to report information on the burden of HCAI. In addition, a limited number of studies in these settings have been published in the scientific literature.

The *Clean Care is Safer Care* team of WHO Patient Safety, in collaboration with the University of Geneva Hospitals, recently published a systematic review and meta-analysis on the endemic burden of HCAI in developing countries.³ Data included in this report represent an update of this work. In our review, covering the period from 1995 to 2010 (Box 1), 276 papers included relevant information on the epidemiology of the four most frequent types of HCAI (SSI, UTI, BSI, health-care associated pneumonia [HAP]/VAP) in low- and middle-income countries. Only 46% (126/276) met the criteria usually defining high-quality epidemiological studies (Box 1).

A review of countries where studies were performed and regional coverage revealed clearly an extremely fragmented picture of the endemic burden of HCAI in the developing world, with very scanty

Figure 4.1
Number of studies* reporting health care-associated infection in low- and middle-income countries, 1995-2010




* Studies with any scope (i.e. conducted at the unit, facility, multicenter, or national level) are included.

information available from some regions (particularly Africa and the Western Pacific) (Figure 4.1). However, even in regions where overall more studies were conducted and published (Europe and the Americas), several countries are covered by several reports, whereas others are not represented by any published surveillance study (Figure 4.1). Brazil, India, Mexico, Thailand, and Turkey were identified as the countries with the highest number of studies. Only nine studies from four countries (Cuba, Mexico, Thailand, and Turkey) were conducted at national level.^{20,25,126-132} An additional 39 multicentre studies were reported from different countries, either conducted in multiple hospitals in one city or in a country territory.^{38,133-169} According to our review, 66% (97/147) of developing countries have no published data at all. The limited number of studies with a broad scope, together with the lack of national surveillance systems, significantly hamper any attempts to estimate the burden of HCAI at country or regional level in low- and middle-income countries. Studies from single hospitals cannot be considered representative of the endemic epidemiology of HCAI in a country. In particular, most studies were conducted in teaching/ university hospitals (144/276 [52.2%]), which represent a specific type of context and not the broad range of health-care settings in place in countries. Most importantly, the HCAI surveillance

programme of the International Nosocomial Infection Control Consortium (INICC) (<http://www.inicc.org/>) is of great assistance to help bridge some of the gaps and to gauge the extent of the problem. This fast-growing network coordinates data collection on device-associated infections in several low- and middle-income countries and has published already four international studies^{158,170-173} and many reports from individual countries or facilities.^{137,139,144,147,174,175}

Many studies conducted in health-care settings with limited resources reported HCAI rates higher than in developed countries. Hospital-wide prevalence of HCAI varied from 5.7% to 19.1% (Figures 3.2 and 4.2) with a pooled prevalence of 10.1 per 100 patients (95% CI 8.4-12.2) and most studies reported proportions of infected patients higher than 10%; the pooled prevalence of affected patients was 10.2 per 100 patients (95% CI 9.0-13.0).^{25,27,126,128-130,149,157,164,166,167,169,176-188} Of note, it was calculated that the pooled HCAI prevalence was significantly higher in high- than in low-quality studies (15.5% vs 8.5%, respectively).³ Similarly, the proportion of infected patients was higher in high-quality studies (13.5% vs 7.2%).³ The most frequent type of infection in these mixed patient populations was SSI (29.1%), followed by UTI (23.9%), BSI (19.1%), HAP (14.8%), and other infections (13.1%).³

Figure 4.2
Prevalence of health care-associated infection in low- and middle-income countries, 1995-2010



- Only 23 developing countries (23/147 [15.6%]) reported a functioning HCAI national surveillance system in 2010.
- No published data on HCAI endemic burden from 66% (97/147) of developing countries, according to the current review.
- HCAI pooled prevalence in mixed patient populations in low- and middle-income countries: 10.1%. In high-quality papers, prevalence: 15.5%.
- SSI is the most frequent HCAI hospital-wide in low- and middle-income countries with a pooled incidence of 11.8 per 100 patients undergoing surgical procedures.
- In low- and middle-income countries, incidence of ICU-acquired infection is at least 2–3 fold higher than in high-income countries; device-associated infection densities up to 13 times higher than in the USA were reported in some studies.

The increased burden of HCAI in low- and middle-income countries affects especially high-risk populations, such as patients admitted to ICUs and newborns, with HCAI frequency several-fold higher than in industrialized countries, particularly for device-associated infections. The proportion of patients with ICU-acquired infection was as high as 35.2% (95% CI 24.2–48.0) (pooled cumulative incidence). The incidence of HCAI ranged from 4.4% up to 88.9%.^{28,137,139,144,147,175,189–195} HCAI incidence density in settings with limited resources significantly varied between 4.1 and 91.7 episodes per 1000 patient-days (Figure 4.3), and pooled cumulative incidence was 42.7 episodes per 1000 patient-days (95% CI 34.8–50.5) (Table 3.1).^{28,135,137,139,144,147,175,189,190,192–196} The latter was significantly higher than reported in the USA (13 per 1000 patient-days)⁷⁷ and in the results of our meta-analysis related to high-income countries (17.0 per 1000 patient-days). Data reported in several studies from Argentina and Turkey indicated that infection density in ICU patients can be higher than 50 per 1000 patient-days.^{28,135,193,194} Pooled cumulative incidence densities of CR-BSI, CR-UTI, and VAP among adult ICU patients in low- and middle-income countries were 12.2 per 1000 CL-days (95% CI 10.5–13.9),^{134–136,138–141,144,147,158,161,162,170,171,175,197–200} 8.8 per 1000 urinary catheter-days (95% CI 7.3–10.4),^{134–141,144,147,158,161,170,171,197,198,201} and 23.9 per 1000 ventilator-days (95% CI 20.7–27.1),^{134–141,144,147,158,161,170,171,175,197,198,202–204} respectively (Table 3.1 and Figure 4.3). These values are higher than those most recently reported by the INICC¹⁵⁸ in a network of ICUs in developing countries and are two- to three-fold higher than in ICUs in high-income countries (Table 3.1 and Figure 3.4). An analysis of individual studies revealed that device-associated infection densities up to 13 times higher than in the USA can be detected.³ Considering that these types of infections are a clear reflection of the safety level of invasive procedures, it is evident that patients in developing countries are at greater risk of being infected through these devices.

A limited number of studies are available on HCAI epidemiology in the paediatric population. According to a systematic review by Zaidi

and colleagues,²⁰⁵ neonatal infection rates in developing countries are three to 20 times higher than in industrialized countries. Among hospital-born babies, these infections are responsible for 4% to 56% of all causes of death in the neonatal period, with three-quarters occurring in the South-East Asia Region and sub-Saharan Africa.

HCAI rates are particularly high in neonatal and paediatric ICUs. Data pooled from four comparable studies conducted in Brazilian neonatal ICUs revealed an overall cumulative incidence as high as 40.8 infections per 100 patients (95% CI 16.1–71.1), and a HCAI incidence density of 30.0 episodes per 1000 patient-days (95% CI 25.0–35.0).³ In studies in neonatal and paediatric ICUs retrieved through our review and as reported also by Zaidi and colleagues, VAP and CR-BSI densities were particularly high, ranging from 10.9 to 143 episodes per 1000 ventilator-days and from 2.1 to 60.0 episodes per 1000 catheter-days, respectively.^{206–216}


Almost half of studies focusing on specific types of infection were related to SSI (62/131),^{36–38,131,150–156,217–244} probably because it can be identified more easily according to clinical criteria. SSI appears to be also the most frequent HCAI hospital-wide in low- and middle-income countries and more than 10% of operated patients usually develop SSI. Reported SSI cumulative incidence ranged from 0.4 to 30.9 per 100 patients undergoing surgical procedures and from 1.2 to 23.6 per 100 surgical procedures.³ SSI pooled rates were 11.8 per 100 patients undergoing surgical procedures (95% CI 8.6–16.0) and 5.6 per 100 surgical procedures (95% CI 2.9–10.5).³ This level of risk for patients undergoing surgical procedures is significantly higher than in developed countries. For example, SSI incidence reached 30.2% in the surgical unit of a university hospital in Brazil.³² Similarly, 30.9% of paediatric patients acquired an infection following surgery in a teaching hospital in Nigeria.²⁴⁵

A recently-published review of microbiological patterns of HCAI from 28 studies conducted in developing countries³ reported gram-negative rods as the most common nosocomial isolates, both in mixed patient populations and in high-risk patients. The most frequent single pathogens were *S. aureus* in mixed patient populations, and *Acinetobacter* spp. in high-risk patients. The latter was the second most frequent pathogen identified for VAP (24.0%) and, unexpectedly, for BSI (17.7%). *S. aureus* was the most frequent cause of both SSI and BSI. Surprisingly, gram-negative rods were isolated in a large proportion of SSIs. A limited number of studies reported data on antimicrobial resistance patterns. Only information on methicillin resistance of *S. aureus* compiled from eight studies was provided and showed that as many as 54.5% of all isolates (158/290) carried this pattern.

Zaidi and colleagues²⁰⁵ previously reported alarming estimates among neonates indicating that 51% of *Klebsiella* spp. were extended-spectrum beta-lactamase-producers, and 38% and 64% of *S. aureus* were resistant to methicillin and co-trimoxazole, respectively. The authors found also that 70% of pathogens isolated in endemic BSI may be resistant to ampicillin and gentamicin, the

antimicrobials recommended by WHO for the empiric therapy of neonatal sepsis. The dramatic paucity of data on antimicrobial resistance of health care-associated pathogens in developing countries was also highlighted by Okeke and colleagues in a comprehensive review on this topic.²⁴⁶

Figure 4.3
Incidence of overall health care-associated infection and device-associated infection in high-risk patients in low- and middle-income countries, 1995-2010



5.

The impact of health care-associated infection worldwide

The burden of HCAI worldwide needs to be highlighted not only because of the large number of patients affected every year, but also for its significant impact in terms of excess costs, prolonged hospital stay, attributable mortality, and other complications. Data on these important indicators are difficult to retrieve as they require complex evaluation, particularly to confirm that they are directly linked to HCAI episodes and not to other factors. Methods of recording and filing patient clinical data vary worldwide, with a limited availability of electronic-based systems in developing countries. Health-care financial systems also differ with a broad range of payer sources (e.g. a governmental agency, private insurance company, or even the patients themselves) and local charges, thus leading to complex estimates and calculations of costs and potentially limiting inter-hospital and international comparisons.

Similar to many other adverse events experienced by patients while seeking health care, HCAIs lead to added suffering and the psychological and financial burden to patients. Given that HCAI is inherently linked to health-care workers' behaviour (e.g. sub-optimal hand hygiene practices) and, in some cases, to health-care system gaps (e.g. lack of adequate equipment), this burden translates into a profound frustration and loss of trust in the system and health-

care professionals. The case of a 13-year-old patient illustrates the incredible long-term suffering, pain, and fear that one HCAI can cause (Patient case story).

Core evidence available from high-income countries

Overall estimates of HCAI impact are available for some high-income countries and help understand the magnitude of its consequences. European estimates indicate that HCAIs cause 16 million extra-days of hospital stay and 37 000 attributable deaths annually, but also contribute to an additional 110 000 deaths.⁷⁶

The burden of HCAI is also reflected in significant financial losses. According to a report from the ECDC, these infections account for approximately € 7 billion per year, including direct costs only.⁷⁶ Recent national estimates from Belgium showed that about 900 000 bed-days are complicated every year by at least one episode of HCAI.⁵² Similar dramatic figures were reported in the USA and around 99 000 deaths were attributed to HCAI in 2002.⁷⁷ Of these, approximately 36 000 were due to pneumonia, 31 000 to BSI, 13 000 to UTI, 8 200 to SSI, and 11 062 to other infections. The annual economic impact of HCAI in the USA was approximately US\$ 6.5 billion in 2004.⁷⁷

Patient case story

My name is Raihama and I am 13 years old. Last year, I was admitted to hospital on 16 July for a gallstone problem and two days later I was operated. It was only three months after the operation that I was finally discharged from the hospital, because I picked up a nosocomial infection. Fortunately, I had a good friend who brought me school work every week and taught me what she had learned in school. She also wrote down all the words and calculations of the homework for me, because the infection had settled in my arm. I have never been able to move my arm as I did before. I can no longer do all I want to do with this arm.

I am Raihama's mother. She developed an infection after her operation and we had a lot of difficulties over those three months. We had to go to several hospitals. In the first hospital, they never accepted that Raihama's infection was due to her operation and nobody helped us take care

of her situation. We had to look for good physicians and paid for all the expenses ourselves. The infection has left irreversible damage on her arm because it spread to the bones. We were told that it was an osteomyelitis.

For three months, I had to leave my two little kids early every morning to go to a hospital far from our home to take care of Raihama and I only got home late in the evening. The kids didn't see me any more and they were very worried for the health of their sister. Nobody was feeling good at home. Now every time Raihama tells me that she has a headache or she doesn't feel well, my heart starts beating fast and I get really worried. I am scared that everything is starting again.

Source: WHO Patients for Patient Safety
(http://www.who.int/patientsafety/patients_for_patient/en/)

In studies mainly conducted in high-income countries, crude mortality rates associated with HCAI vary from 12% to 80%, depending on the patient population.⁹⁰ As mentioned previously, estimating the excess mortality due to HCAI is challenging, especially in high-risk patients who are at greater risk of death because of severe underlying diseases. For example, Soufir and colleagues²⁴⁷ reported that crude mortality rates were significantly higher in critically-ill patients affected by CR-BSI compared to those non-affected (50% vs 21%, respectively). When adjusting for admission prognostic factors, infection remained associated with mortality, but not after taking into account severity scores before infection onset. Several additional studies brought controversial results, some corroborating the hypothesis that HCAI patients are at higher risk of death. Among these, a prevalence study conducted in 17 Western European countries showed that clinical sepsis, pneumonia, and BSI were all independently associated with an increased risk of death in critically-ill patients.²⁴⁸

Of note, according to studies conducted in high-income countries, some infections, such as VAP and BSI, have a more severe impact than others. VAP attributable mortality has been estimated at between 7% and 30% and attributable costs at US\$ 10 000–25 000 per case.^{249,250} Of approximately 250 000 CR-BSI occurring every year hospital-wide in the USA, about 28 000 lead to deaths in ICU patients, with an annual cost of up to US\$ 2.3 billion.²⁵¹ Furthermore, in a recent study performed in four European countries, additional length of stay per CR-BSI episode varied between 4 and 14 days. Additional associated costs per episode ranged from € 4 200 to € 13 030, representing annual costs to health-care systems of between € 53.9 million in the United Kingdom and € 130 million in France.²⁵²

- In Europe, HCAs cause 16 million extra-days of hospital stay and 37 000 attributable deaths (and contribute to an additional 110 000). Associated costs: approximately € 7 billion annually.
- In the USA, around 99 000 deaths were attributed to HCAI in 2002. Associated costs: approximately US\$ 6.5 billion in 2004.
- VAP attributable mortality: between 7% and 30%; VAP attributable costs: US\$ 10 000–25 000 per case.
- CR-BSI additional length of stay: 4–14 days. Additional associated costs per episode in European countries: € 4 200–13 030.

Core evidence available from low- and middle-income countries

Very limited data are available at the national level to assess the impact of HCAI in low- and middle-income countries. Conversely, an increasing body of information has been published at the institutional level. We identified 89 studies reporting data on the

burden of HCAI in terms of mortality, costs and increased length of stay in health-care settings.^{20,22,24-28,126,133,135,138,139,142-146,148, 158,160,164,170,175, 177,180,189,190,193,195,206,208,210,211,214-216,218,224,226,227,230,232,233,235,237,238,239,253-292}

However, in most cases, only crude mortality rates in patients affected by HCAI were reported, without taking into account other risk factors or major confounders, or by comparing these with non-infected patients. Thus, no conclusions can be drawn on the risk of death actually attributable to HCAI. Several studies reported significantly higher mortality in infected patients, in particular in paediatric and adult ICUs.^{133,135,139,194,211,216,261,269,273,277} According to the 2003-2008 INICC report related to 173 ICUs in Latin America, Asia, Africa, and Europe, crude excess mortality in adult patients was 18.5%, 23.6% and 29.3%, for CR-UTI, CR-BSI and VAP, respectively.¹⁵⁸ Increased length of stay associated with HCAI varied between 5 and 29.5 days.^{22,24,126,133,135,139,143,160,175,189,193,194,206,210,211,214-216,218,230,237-239,253,257,260,265,267,274,282,283,289,290,292,293}

In a multicentre study conducted in ICUs in India, excess length of stay and mortality due to VAP, CR-UTI, and CR-BSI were 11, 8 and 5 days, and 19.0%, 11.6%, and 4.0%, respectively.¹³⁹ In an Argentinean ICU, the attributable mortality from VAP, CR-UTI, and CR-BSI was 35.0%, 25.0%, and 5.0%, respectively.¹³⁵ Wide variations in cost estimates associated with HCAI were observed between countries. The economic impact in Belo Horizonte, Brazil, was estimated to be equal to US\$ 18 million in 1992, based on costing information from the USA and Costa Rica.¹⁶⁴ In an 800-bed, tertiary care, university hospital in Malaysia with a HCAI prevalence of 13.9 per 100 patients, the cost of antibiotics prescribed to treat HCAI was estimated at US\$ 521 000 per year.¹⁸⁰ Costs associated with hospital-acquired BSI in cardiac surgical patients in a hospital in India averaged US\$ 22 873 and represented an excess cost of US\$ 14 818 per case compared with non-infected patients.²⁷³ In Mexican ICUs, the overall average cost of a HCAI episode was US\$ 12 155 with an excess cost of US\$ 11 591 per case of CR-BSI.^{143,279} In several ICUs in Argentina, the overall extra-cost estimates for CR-BSI and HAP averaged US\$ 4888 and US\$ 2255 per case, respectively.^{133,294}

- Increased length of stay associated with HCAI in developing countries: 5-29.5 days.
- Excess mortality due to HCAI in adult patients in Latin America, Asia, Africa: 18.5%, 23.6%, and 29.3%, for CR-UTI, CR-BSI, and VAP, respectively.
- Economic impact of HCAI in Belo Horizonte, Brazil, in 1992: US\$ 18 million.
- In Mexican ICUs, overall average cost of a HCAI episode: US\$ 12 155.
- In ICUs in Argentina, overall extra-costs for CR-BSI and HAP: US\$ 4 888 and US\$ 2 255 per case, respectively.

6

Lessons learned and the way forward

By mapping and scrutinizing the studies in the scientific literature, a global picture of the endemic burden of HCAI can be captured for the first time with compiled data from many countries and, importantly, an assessment of differences between high-, low- and middle-income countries. The key finding is that the burden of HCAI worldwide is very high in terms of morbidity, mortality, extra-costs, and other outcome indicators. This is particularly true for developing countries where awareness of the problem remains extremely limited, and because other health priorities take precedence over patient safety considerations.

Of every 100 hospitalized patients at any given time, 7 and 10 of them will acquire a HCAI in developed and developing countries, respectively. According to high-quality studies, this proportion increases to 15 per 100 patients in developing countries.³ HCAI is more frequent in critically-ill patients admitted to ICUs. In this patient population, the increased risk in settings with limited resources is particularly disturbing with an overall frequency of infection as high as 42.7 episodes per 1000 patient-days in developing countries vs 17.0 episodes per 1000 patient-days in industrialized countries. Furthermore, in these high-risk settings, incidence densities of infections associated with the use of invasive devices (central vascular lines, ventilators and urinary catheters) are on average at least three-fold higher in low- and middle-income than in high-income countries (Figures 3.4 and 4.3). Pooled incidence density of CR-BSI and VAP in some developing countries were even shown to be up to 19 and 16 times higher than those reported from Germany and the USA.³ Newborns are also at higher risk of acquiring HCAI, with infection rates in developing countries three to 20 times higher than in high-income countries.²⁰⁵

Interestingly, UTI, especially related to urinary catheter use, is the most frequent infection detected hospital-wide in mixed patient populations in high-income countries. However, this type of infection has usually less severe consequences than other device-associated infections in terms of attributable mortality, related complications, and associated costs. Conversely, in low- and middle-income countries, SSI is the most frequent HCAI and affects up to one-third of operated patients. Frequencies reported for SSI are probably largely underestimated as, according to some studies, most are detected through post-discharge surveillance, which is very difficult to perform in developing countries.³²⁻³⁸ SSI can prolong hospital stay up to 21 days in settings with limited resources.²³⁰ In addition, it can bring a huge burden in terms of medium-term sequelae, personal suffering for the patient, and additional financial costs.

With regard to data availability, this report shows that information at the national level is regularly provided by several national surveillance systems and international networks in high-income countries. By contrast, very few national studies are available from low- and middle-income countries and the vast majority has no regular HCAI reporting system in place. Furthermore, even when considering studies related to single institutions, data are not available for many developing countries and some regions are poorly represented overall (Figure 4.1).

Although national figures on the burden of HCAI are available only for a few countries, based on data from Europe and the USA, it can be estimated that hundreds of millions of patients suffer from HCAI every year worldwide. However, it is important to note that infections acquired by health-care workers, data on outbreaks and blood-borne pathogens transmitted through transfusion, contaminated injections, and other procedures are not included in these estimates. For this reason, and because of reporting gaps even when surveillance systems are in place, the burden of HCAI is certainly greatly underestimated.

Raw data related to the number of affected patients and number of episodes per patient, together with a valid and accurate denominator (e.g. number of patients hospitalized for more than 48 hours) are not available from most countries. In addition, no system exists to collate these data on a global level, as is the case for other diseases annually reported by WHO. This is mainly due to constraints inherent to HCAI surveillance that include: the complexity of HCAI diagnosis (including lack of specific diagnostic tests, such as those available for human immunodeficiency virus (HIV), tuberculosis, and malaria); neglected use of standardized



© University of Geneva Hospitals

definitions; lack of expertise and dedicated personnel; and the overall lack of financial resources to invest in this field. Further research is very much needed to identify mathematical models in order to obtain more predictive global estimates of HCAI. Although these should be partly based on findings from published epidemiological reports, the reliability of the study results must be considered as the quality can be very poor, particularly those conducted in developing countries. In addition, minimum requirements and standards should be set to allow countries to establish robust surveillance systems and report national figures. Case definitions need to be homogenized, together with the method of calculating the denominator, e.g. calculation of days at-risk until the first infectious episode or for the entire period of hospitalization. Adaptation of definitions to make HCAI detection more feasible in settings with limited resources should be considered and validated through scientifically sound investigations. Standardization would help to gather a more comprehensive picture and to optimize inter-hospital and international comparisons. Ideally, countries should adopt definitions and methods used by prominent surveillance networks, such as HELICS, NHSN, KISS and INICC. It would be also important to encourage these networks to join their efforts and use the same definitions, and even to explore possibilities to merge their data on a regular basis.

Evaluation of the key determinants of HCAI burden is complex, but it remains an essential step to identify strategies and measures for improvement. In advanced settings in high-income countries, HCAI may occur as a potentially expected adverse event of sophisticated care techniques and treatments typical of modern medicine. However, it is also evident that frequently it represents a health-care delivery system failure. Despite the broader availability of resources

in these settings, awareness and knowledge of HCAI are often poor, and well-known, evidence-based, infection prevention and control strategies could be enforced and implemented more effectively.

In developing countries, the nature of this problem is partially different because, in addition to general determinants similar to high-income countries, a combination of numerous unfavourable factors play an important role to increase the risk of HCAI. These are much more inherent to the situation and reality of these countries, such as poor hygiene and sanitation, lack or shortage of basic equipment, inadequate infrastructures, unfavourable social background, and a population largely affected by malnutrition and other types of infection and/or diseases.

Data from this report highlighting the serious burden of HCAI bring strong evidence that these determinants, as well as surveillance issues, must be carefully assessed and tackled as much as possible at all levels if any significant progress is to be made in the future. Table 6.1 summarizes the most relevant actions and perspectives for the improvement of HCAI surveillance and control.

Table 6.1
Key solutions and perspectives for improvement of HCAI surveillance and control

Solutions and perspectives for improvement

- Identifying local determinants of the HCAI burden.
- Improving reporting and surveillance systems at the national level.
- Ensuring minimum requirements in terms of facilities and dedicated resources available for HCAI surveillance at the institutional level, including microbiology laboratories' capacity.
- Ensuring that core components for infection control are in place at the national and health-care setting levels.
- Implementing standard precautions, particularly best hand hygiene practices at the bedside.
- Improving staff education and accountability.
- Conducting research to adapt and validate surveillance protocols based on the reality of developing countries.
- Conducting research on the potential involvement of patients and their families in HCAI reporting and control.

Robust evidence exists that HCAI can be prevented and the burden reduced by as much as 50% or more.^{41,173,295-298} Solid recommendations have been issued by national and international organizations,^{7,251,299-305} but their application need to be strengthened and accompanied by performance monitoring both in high-, low- and middle-income countries. Furthermore, this body of evidence has accumulated mostly through studies conducted in industrialized countries and these strategies may





© University of Geneva Hospitals

not always be applicable to settings with limited resources and different social and cultural backgrounds. However, it is noteworthy that very encouraging results from an increasing number of infection control interventions and programmes implemented in developing countries have been reported over the last decade. For instance, ICUs participating in the surveillance and infection control programmes coordinated by INICC have documented a substantial decrease of CR-BSI and CR-UTI over recent years.^{137-139,141,144,147,170,171,196} In addition, adaptations of hand hygiene promotion strategies have proved to be feasible and successful to improve practices^{187,306-308} and, in several cases, to reduce HCAI^{196,236,309} in settings with limited resources.

It is imperative that core components for infection prevention and control be put in place before any specific measures or “bundles” are implemented, and these were recently identified at the institutional level by WHO.³¹⁰ Among these, very important aspects concern the implementation of standard and isolation precautions,^{299,301,305} environmental cleaning,^{311,312} water and sanitation in health-care settings,³¹¹ sterilization and disinfection procedures,^{313,314} and infectious waste and sharp disposal, including other specific measures for injection safety.^{311,315,316} Antimicrobial resistance (http://www.who.int/topics/drug_resistance/en/) should also be tackled with appropriate multi-disciplinary strategies, including infection control measures, as health care-associated pathogens often carry patterns of multi-drug resistance, well known to bring more virulence.³¹⁷

By definition, HCAI affects also health-care workers and the promotion of protective measures and best practices should be among key priorities to reduce the burden of HCAI.³¹⁸ Staff education is a key element of all multimodal approaches and requires relatively limited efforts. It is now recognized that the basic principles of infection control should be included in the curricula of medical, nursing, and other healthcare professions and WHO has taken the initiative to issue guidelines for their content.^{319,320} Finally, and most importantly, HCAI must be treated as a priority patient safety issue within comprehensive approaches to be tackled effectively. These include quality improvement and reporting and learning mechanisms, visible commitment by decision-makers and health-care administrators, increased individual accountability among health-care workers and, possibly, patient involvement.³²¹

WHO Patient Safety actively works towards establishing the most effective ways in which to improve global health care and save lives lost to HCAI (<http://www.who.int/patientsafety/en/>). Among these, the *Clean Care is Safer Care* programme is aimed at reducing the burden of HCAI worldwide with improvement of hand hygiene practices as the core component (<http://www.who.int/gpsc/en/>). WHO Patient Safety closely collaborates with other programmes at headquarters, including regional and country offices supporting Member States, to reduce HCAI by assisting with the assessment, planning, and implementation of infection prevention and control policies, and timely actions at national and institutional levels.

REFERENCES

- Bates DW et al. Global priorities for patient safety research. *British Medical Journal*, 2009, 338:b1775.
- Burke JP. Infection control - a problem for patient safety. *New England Journal of Medicine*, 2003, 348:651–656.
- Allegranzi B et al. Burden of endemic health care-associated infection in developing countries: systematic review and meta-analysis. *Lancet*, 2011, 377:228–241.
- The global burden of disease: 2004 update*. Geneva, World Health Organization, 2008.
- Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. *American Journal of Infection Control*, 2008, 36:309–332.
- World Bank list of economies*. Washington, DC, The World Bank, 2009.
- Prevention of hospital-acquired infections: a practical guide*. Geneva, World Health Organization, 2002:64.
- Cole M. Infection control: worlds apart primary and secondary care. *British Journal of Community Nursing*, 2007, 12:301,303–306.
- Pellowe CM et al. Evidence-based guidelines for preventing healthcare-associated infections in primary and community care in England. *Journal of Hospital Infection*, 2003, 55(Suppl. 2):S2–127.
- Manangan LP et al. Feasibility of national surveillance of health-care-associated infections in home-care settings. *Emerging Infectious Diseases*, 2002, 8:233–236.
- Moro ML et al. The burden of healthcare-associated infections in European long-term care facilities. *Infection Control and Hospital Epidemiology*, 2010, 31(Suppl. 1):S59–S62.
- Moro ML, Mongardi M, Marchi M. Healthcare-related infections outside the hospital: a new frontier for infection control. *New Microbiologica*, 2007, 30:350–354.
- Eriksen HM et al. Healthcare-associated infection among residents of long-term care facilities: a cohort and nested case-control study. *Journal of Hospital Infection*, 2007, 65:334–340.
- Gravel D et al. Point prevalence survey for healthcare-associated infections within Canadian adult acute-care hospitals. *Journal of Hospital Infection*, 2007, 66:243–248.
- Maugat S, Carbonne A, Astagneau P. [Significant reduction of nosocomial infectious: stratified analysis of prevalence national studies performed in 1996 and 2001 in French north interregion]. *Pathologie Biologie (Paris)*, 2003, 51:483–489.
- Kritsotakis EI et al. Case-mix adjustment approach to benchmarking prevalence rates of nosocomial infection in hospitals in Cyprus and Greece. *Infection Control and Hospital Epidemiology*, 2008, 29:685–692.
- Klavs I et al. Prevalence of and risk factors for hospital-acquired infections in Slovenia – results of the first national survey, 2001. *Journal of Hospital Infection*, 2003, 54:149–157.
- Lanini S et al. Healthcare-associated infection in Italy: annual point-prevalence surveys, 2002-2004. *Infection Control and Hospital Epidemiology*, 2009, 30:659–665.
- de Gentile A et al. Nosocomial infections in a children's hospital in Argentina: impact of a unique infection control intervention program. *Infection Control and Hospital Epidemiology*, 2001, 22:762–766.
- Avila-Figueroa C et al. [Prevalence of nosocomial infections in children: survey of 21 hospitals in Mexico]. *Salud Pública de México*, 1999, 41(Suppl. 1):S18–S25.
- Tapia-Rombo CA et al. Risk factors for intrahospital infection in newborns. *Archives of Medical Research*, 2001, 32:304–311.
- Hajdu A et al. A point prevalence survey of hospital-acquired infections and antimicrobial use in a paediatric hospital in north-western Russia. *Journal of Hospital Infection*, 2007, 66:378–384.
- Pawa AK et al. Neonatal nosocomial infection: profile and risk factors. *Indian Pediatrics*, 1997, 34:297–302.
- Ben Jaballah N et al. [Epidemiology of nosocomial bacterial infections in a neonatal and pediatric Tunisian intensive care unit]. *Médecine et Maladies Infectieuses*, 2006, 36:379–385.
- Izquierdo-Cubas F et al. National prevalence of nosocomial infections. Cuba 2004. *Journal of Hospital Infection*, 2008, 68:234–240.
- Sallam SA et al. Device-related nosocomial infection in intensive care units of Alexandria University Students Hospital. *Eastern Mediterranean Health Journal*, 2005, 11:52–61.
- Dia NM et al. [Prevalence of nosocomial infections in a university hospital (Dakar, Senegal)]. *Médecine et Maladies Infectieuses*, 2008, 38:270–274.
- Cevik MA et al. Relationship between nosocomial infection and mortality in a neurology intensive care unit in Turkey. *Journal of Hospital Infection*, 2005, 59:324–330.
- Fernandez-Ayala M et al. Surgical site infection during hospitalization and after discharge in patients who have undergone cardiac surgery. *Infection Control and Hospital Epidemiology*, 2006, 27:85–88.
- Huenger F et al. Evaluation of postdischarge surveillance of surgical site infections after total hip and knee arthroplasty. *American Journal of Infection Control*, 2005, 33:455–462.
- Mitt P et al. Surgical-site infections following cesarean section in an Estonian university hospital: postdischarge surveillance and analysis of risk factors. *Infection Control and Hospital Epidemiology*, 2005, 26:449–454.
- Oliveira AC, Carvalho DV. Postdischarge surveillance: the impact on surgical site infection incidence in a Brazilian university hospital. *American Journal of Infection Control*, 2004, 32:358–361.
- Santos KR et al. Incidence surveillance of wound infection in hernia surgery during hospitalization and after discharge in a university hospital. *Journal of Hospital Infection*, 1997, 36:229–233.
- Wagner MB et al. Hospital-acquired infections among surgical patients in a Brazilian hospital. *Journal of Hospital Infection*, 1997, 35:277–285.
- Ferraz EM et al. Postdischarge surveillance for nosocomial wound infection: does judicious monitoring find cases? *American Journal of Infection Control*, 1995, 23:290–294.
- Giri BR et al. Surgical site infection and antibiotics use pattern in a tertiary care hospital in Nepal. *Journal of Pakistan Medical Association*, 2008, 58:148–151.
- Eriksen HM et al. Surgical-site infections at Kilimanjaro Christian Medical Center. *Journal of Hospital Infection*, 2003, 55:14–20.
- Kasatpibal N et al. Risk of surgical site infection and efficacy of antibiotic prophylaxis: a cohort study of appendectomy patients in Thailand. *BMC Infectious Diseases*, 2006, 6:111.

39. Pittet D et al. Evidence-based model for hand transmission during patient care and the role of improved practices. *Lancet Infectious Diseases*, 2006, 6:641–652.
40. *CDC surveillance update*. Atlanta, GA, Centers for Disease Control and Prevention, 1988.
41. Haley RW et al. The efficacy of infection surveillance and control programs in preventing nosocomial infections in U.S. hospitals. *American Journal of Epidemiology*, 1985, 121:182–205.
42. Schwab F et al. Reducing neonatal nosocomial bloodstream infections through participation in a national surveillance system. *Journal of Hospital Infection*, 2007, 65:319–325.
43. Gastmeier P et al. Effectiveness of a nationwide nosocomial infection surveillance system for reducing nosocomial infections. *Journal of Hospital Infection*, 2006, 64:16–22.
44. Moro ML et al. Rates of surgical-site infection: an international comparison. *Infection Control and Hospital Epidemiology*, 2005, 26:442–448.
45. Mannien J et al. Impact of postdischarge surveillance on surgical site infection rates for several surgical procedures: results from the nosocomial surveillance network in The Netherlands. *Infection Control and Hospital Epidemiology*, 2006, 27:809–816.
46. *Annual epidemiological report on communicable diseases in Europe 2010*. Stockholm, European Centre for Disease Prevention and Control, 2010:1–185.
47. Gastmeier P et al. Prevalence of nosocomial infections in representative German hospitals. *Journal of Hospital Infection*, 1998, 38:37–49.
48. Nicholls TM, Morris AJ. Nosocomial infection in Auckland Healthcare hospitals. *New Zealand Medical Journal*, 1997, 110:314–316.
49. Thiolet J et al. Prevalence of nosocomial infections, France, 2006. *Bulletin Epidémiologique Hebdomadaire*, 2007, 51-52:429–432.
50. Lizioli A et al. Prevalence of nosocomial infections in Italy: result from the Lombardy survey in 2000. *Journal of Hospital Infection*, 2003, 54:141–148.
51. Lepoutre A et al. *Deuxième enquête nationale de prévalence des infections nosocomiales, France, 2001: réseau d'alerte d'investigation et de surveillance des infections nosocomiales*. St Maurice, Institut de veille sanitaire, 2005:11.
52. Gordts B et al. The 2007 Belgian national prevalence survey for hospital-acquired infections. *Journal of Hospital Infection*, 2010, 75:163–167.
53. Floret N et al. Results from a four-year study on the prevalence of nosocomial infections in Franche-Comté: attempt to rank the risk of nosocomial infection. *Journal of Hospital Infection*, 2006, 63:393–398.
54. Sartor C et al. Assessment of the value of repeated point-prevalence surveys for analyzing the trend in nosocomial infections. *Infection Control and Hospital Epidemiology*, 2005, 26:369–373.
55. van der Kooij TI et al. Prevalence of nosocomial infections in The Netherlands, 2007–2008: results of the first four national studies. *Journal of Hospital Infection*, 75:168–172.
56. The French Prevalence Survey Study Group. Prevalence of nosocomial infections in France: results of the nationwide survey in 1996. *Journal of Hospital Infection*, 2000, 46:186–193.
57. Pellizzer G et al. Prevalence and risk factors for nosocomial infections in hospitals of the Veneto region, north-eastern Italy. *Infection*, 2008, 36:112–119.
58. Vaque J, Rossello J, Arribas JL. Prevalence of nosocomial infections in Spain: EPINE study 1990–1997. EPINE Working Group. *Journal of Hospital Infection*, 1999, 43(Suppl.):S105–S111.
59. Vaque J et al. Nosocomial infections in Spain: results of five nationwide serial prevalence surveys (EPINE Project, 1990 to 1994). Nosocomial Infections Prevalence Study in Spain. *Infection Control and Hospital Epidemiology*, 1996, 17:293–297.
60. Sax H, Pittet D. [pour le comité de rédaction de *Swiss-NOSO* et le réseau *Swiss-NOSO Surveillance*]. Résultats de l'enquête nationale de prévalence des infections nosocomiales de 2004 (snip04). *Swiss-NOSO*, 2005, 12:1–4.
61. Gikas A et al. Prevalence of nosocomial infections after surgery in Greek hospitals: results of two nationwide surveys. *Infection Control and Hospital Epidemiology*, 2004, 25:319–324.
62. Nicastrì E et al. Prevalence of nosocomial infections in 15 Italian hospitals: first point prevalence study for the INF-NOS project. *Infection*, 2003, 31(Suppl. 2):10–15.
63. Smyth ET et al. Four country healthcare associated infection prevalence survey 2006: overview of the results. *Journal of Hospital Infection*, 2008, 69:230–248.
64. Sax H. [Nationwide surveillance of nosocomial infections in Switzerland-methods and results of the Swiss nosocomial infection prevalence studies (SNIP) in 1999 and 2002]. *Therapeutische Umschau*, 2004, 61:197–203.
65. Lyytikäinen O et al. Healthcare-associated infections in Finnish acute care hospitals: a national prevalence survey, 2005. *Journal of Hospital Infection*, 2008, 69:288–294.
66. Gikas A et al. Prevalence study of hospital-acquired infections in 14 Greek hospitals: planning from the local to the national surveillance level. *Journal of Hospital Infection*, 2002, 50:269–275.
67. Durando P et al. Surveillance of hospital-acquired infections in Liguria, Italy: results from a regional prevalence study in adult and paediatric acute-care hospitals. *Journal of Hospital Infection*, 2009, 71:81–87.
68. Emmerson AM et al. The second national prevalence survey of infection in hospitals—overview of the results. *Journal of Hospital Infection*, 1996, 32:175–190.
69. Reilly J et al. Results from the Scottish national HAI prevalence survey. *Journal of Hospital Infection*, 2008, 69:62–68.
70. Golliot F et al. Nosocomial infections in geriatric long-term-care and rehabilitation facilities: exploration in the development of a risk index for epidemiological surveillance. *Infection Control and Hospital Epidemiology*, 2001, 22:746–753.
71. Pittet D et al. Prevalence and risk factors for nosocomial infections in four university hospitals in Switzerland. *Infection Control and Hospital Epidemiology*, 1999, 20:37–42.
72. Eriksen HM, Iversen BG, Aavitsland P. Prevalence of nosocomial infections in hospitals in Norway, 2002 and 2003. *Journal of Hospital Infection*, 2005, 60:40–45.
73. Scheel O, Stormark M. National prevalence survey on hospital infections in Norway. *Journal of Hospital Infection*, 1999, 41:331–335.
74. Zotti CM et al. Hospital-acquired infections in Italy: a region wide prevalence study. *Journal of Hospital Infection*, 2004, 56:142–149.
75. Di Pietrantonio C, Ferrara L, Lomolino G. Multicenter study of the prevalence of nosocomial infections in Italian hospitals. *Infection Control and Hospital Epidemiology*, 2004, 25:85–87.
76. *Annual epidemiological report on communicable diseases in Europe 2008. Report on the state of communicable diseases in the EU and EEA/EFTA countries*. Stockholm, European Centre for Disease Prevention and Control, 2008.
77. Klevens RM et al. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. *Public Health Reports*, 2007, 122:160–166.
78. Rioux C, Grandbastien B, Astagneau P. The standardized incidence ratio as a reliable tool for surgical site infection surveillance. *Infection Control and Hospital Epidemiology*, 2006, 27:817–824.
79. Rioux C, Grandbastien B, Astagneau P. Impact of a six-year control programme on surgical site infections in France: results of the INCISO surveillance. *Journal of Hospital Infection*, 2007, 66:217–223.
80. Gulacsi L et al. Risk-adjusted infection rates in surgery: a model for outcome measurement in hospitals developing new quality improvement programmes. *Journal of Hospital Infection*, 2000, 44:43–52.

81. Petrosillo N et al. Surgical site infections in Italian hospitals: a prospective multicenter study. *BMC Infectious Diseases*, 2008, 8:34.
82. Fiorio M et al. Incidence of surgical site infections in general surgery in Italy. *Infection*, 2006, 34:310–314.
83. Geubbels EL et al. An operating surveillance system of surgical-site infections in The Netherlands: results of the PREZIES national surveillance network. [Preventie van Ziekenhuisinfecties door Surveillance.] *Infection Control and Hospital Epidemiology*, 2000, 21:311–318.
84. Gaynes RP et al. Surgical site infection (SSI) rates in the United States, 1992–1998: the National Nosocomial Infections Surveillance System basic SSI risk index. *Clinical Infectious Diseases*, 2001, 33(Suppl. 2):S69–S77.
85. Carlet J et al. French national program for prevention of healthcare-associated infections and antimicrobial resistance, 1992–2008: positive trends, but perseverance needed. *Infection Control and Hospital Epidemiology*, 2009, 30:737–745.
86. Astagneau P et al. Reducing surgical site infection incidence through a network: results from the French ISO-RAISIN surveillance system. *Journal of Hospital Infection*, 2009, 72:127–134.
87. Szilagyi E et al. The national nosocomial surveillance network in Hungary: results of two years of surgical site infection surveillance. *Journal of Hospital Infection*, 2009, 71:74–80.
88. Horwitz JR et al. Pediatric wound infections: a prospective multicenter study. *Annals of Surgery*, 1998, 227:553–558.
89. Vincent JL et al. International study of the prevalence and outcomes of infection in intensive care units. *Journal of the American Medical Association*, 2009, 302:2323–2329.
90. Vincent JL. Nosocomial infections in adult intensive-care units. *Lancet*, 2003, 361:2068–2077.
91. Gikas A et al. Device-associated infections in the intensive care units of Cyprus: results of the first national incidence study. *Infection*, 2010, 38:165–171.
92. Legras A et al. Nosocomial infections: prospective survey of incidence in five French intensive care units. *Intensive Care Medicine*, 1998, 24:1040–1046.
93. Richards MJ et al. Nosocomial infections in combined medical-surgical intensive care units in the United States. *Infection Control and Hospital Epidemiology*, 2000, 21:510–515.
94. Richards MJ et al. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. *Critical Care Medicine*, 1999, 27:887–892.
95. Maugat S et al. [Standardized incidence ratio: a risk index for catheter-related infection surveillance in intensive care units (REACAT network) in Northern France]. *Revue d'Epidémiologie et de Santé Publique*, 2005, 53(Suppl. 1):S39–S46.
96. Gastmeier P, Weist K, Ruden H. Catheter-associated primary bloodstream infections: epidemiology and preventive methods. *Infection*, 1999, 27(Suppl. 1):S1–S6.
97. Hansen S et al. National influences on catheter-associated bloodstream infection rates: practices among national surveillance networks participating in the European HELICS project. *Journal of Hospital Infection*, 2009, 71:66–73.
98. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2003, issued August 2003. *American Journal of Infection Control*, 2003, 31:481–498.
99. Martone WJ et al. National Nosocomial Infections Surveillance (NNIS) semiannual report, May 1995. A report from the National Nosocomial Infections Surveillance (NNIS) system. *American Journal of Infection Control*, 1995, 23:377–385.
100. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992–April 2000, issued June 2000. *American Journal of Infection Control*, 2000, 28:429–448.
101. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. *American Journal of Infection Control*, 2004, 32:470–485.
102. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 to June 2002, issued August 2002. *American Journal of Infection Control*, 2002, 30:458–475.
103. National Nosocomial Infections Surveillance (NNIS) system report, data summary from October 1986–April 1998, issued June 1998. *American Journal of Infection Control*, 1998, 26:522–533.
104. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1990–May 1999, issued June 1999. *American Journal of Infection Control*, 1999, 27:520–532.
105. National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986–April 1996, issued May 1996. A report from the National Nosocomial Infections Surveillance (NNIS) system. *American Journal of Infection Control*, 1996, 24:380–388.
106. National Nosocomial Infections Surveillance (NNIS) report, data summary from October 1986–April 1997, issued May 1997. A report from the NNIS system. *American Journal of Infection Control*, 1997, 25:477–487.
107. Edwards JR et al. National Healthcare Safety Network (NHSN) report, data summary for 2006 through 2007, issued November 2008. *American Journal of Infection Control*, 2008, 36:609–626.
108. Larson EL, Quiros D, Lin SX. Dissemination of the CDC's hand hygiene guideline and impact on infection rates. *American Journal of Infection Control*, 2007, 35:666–675.
109. Edwards JR et al. National Healthcare Safety Network (NHSN) report: data summary for 2006 through 2008, issued December 2009. *American Journal of Infection Control*, 2009, 37:783–805.
110. Edwards JR et al. National Healthcare Safety Network (NHSN) report, data summary for 2006, issued June 2007. *American Journal of Infection Control*, 2007, 35:290–301.
111. Suka M et al. Incidence and outcomes of ventilator-associated pneumonia in Japanese intensive care units: the Japanese nosocomial infection surveillance system. *Infection Control and Hospital Epidemiology*, 2007, 28:307–313.
112. Krankenhaus-Infektions-Surveillance-System (KISS). [Modul ITS-KISS-Referenzdaten-Berechnungszeitraum: Januar 2005 bis Dezember 2009.] Berlin, Nationales Referenzzentrum für Surveillance von nosokomialen Infektionen, 2010.
113. Réseau REA-Raisin. [Surveillance des infections nosocomiales en réanimation adulte. Résultats 2006.] Paris, Institut de veille sanitaire, 2007:1–46.
114. Malacarne P et al. Building a continuous multicenter infection surveillance system in the intensive care unit: findings from the initial data set of 9,493 patients from 71 Italian intensive care units. *Critical Care Medicine*, 2008, 36:1105–1113.
115. Malacarne P et al. Epidemiology of nosocomial infection in 125 Italian intensive care units. *Minerva Anestesiologica*, 2010, 76:13–23.
116. Suka M, Yoshida K, Takezawa J. Epidemiological approach to nosocomial infection surveillance data: the Japanese nosocomial infection surveillance system. *Environmental Health and Preventive Medicine*, 2008, 13:30–35.
117. Olaechea PM et al. Factors related to hospital stay among patients with nosocomial infection acquired in the intensive care unit. *Infection Control and Hospital Epidemiology*, 2003, 24:207–213.
118. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992–June 2001, issued August 2001. *American Journal of Infection Control*, 2001, 29:404–421.
119. Aziz K et al. Variations in rates of nosocomial infection among Canadian neonatal intensive care units may be practice-related. *BMC Pediatrics*, 2005, 5:22.

120. Geffers C et al. Use of central venous catheter and peripheral venous catheter as risk factors for nosocomial bloodstream infection in very-low-birth-weight infants. *Infection Control and Hospital Epidemiology*, 2010, 31:395–401.
121. Richards MJ et al. Nosocomial infections in pediatric intensive care units in the United States. National Nosocomial Infections Surveillance system. *Pediatrics*, 1999, 103:e39.
122. Gastmeier P et al. Risk factors for death due to nosocomial infection in intensive care unit patients: findings from the Krankenhaus Infektions Surveillance System. *Infection Control and Hospital Epidemiology*, 2007, 28:466–472.
123. De Rosa FG et al. SPIR01 and SPIR02: a two-year 1-day point prevalence multicenter study of infections in intensive care units in Piedmont, Italy. *New Microbiologica*, 2008, 31:81–87.
124. Spencer RC. Predominant pathogens found in the European Prevalence of Infection in Intensive Care study. *European Journal of Clinical Microbiology and Infectious Diseases*, 1996, 15:281–285.
125. Kim JM et al. Multicenter surveillance study for nosocomial infections in major hospitals in Korea. Nosocomial infection surveillance committee of the Korean Society for Nosocomial Infection Control. *American Journal of Infection Control*, 2000, 28:454–458.
126. Danchaivijitr S et al. Prevalence and impacts of nosocomial infection in Thailand 2001. *Journal of the Medical Association of Thailand*, 2005, 88(Suppl. 10):S1–S9.
127. Danchaivijitr S et al. Development of quality indicators of nosocomial infection control. *Journal of the Medical Association of Thailand*, 2005, 88(Suppl. 10):S75–S82.
128. Danchaivijitr S et al. Efficacy of hospital infection control in Thailand 1988–1992. *Journal of Hospital Infection*, 1996, 32:147–153.
129. Danchaivijitr S, Tangtrakool T, Chokloikaew S. The second Thai national prevalence study on nosocomial infections 1992. *Journal of the Medical Association of Thailand*, 1995, 78(Suppl. 2):S67–S72.
130. Danchaivijitr S et al. Prevalence of nosocomial infection in Thailand 2006. *Journal of the Medical Association of Thailand*, 2007, 90:1524–1529.
131. Danchaivijitr S et al. A national study on surgical wound infections 1992. *Journal of the Medical Association of Thailand*, 1995, 78(Suppl. 2):S73–S77.
132. Leblebicioglu H, Esen S. Hospital-acquired urinary tract infections in Turkey: a nationwide multicenter point prevalence study. *Journal of Hospital Infection*, 2003, 53:207–210.
133. Rosenthal VD et al. The attributable cost and length of hospital stay because of nosocomial pneumonia in intensive care units in 3 hospitals in Argentina: a prospective, matched analysis. *American Journal of Infection Control*, 2005, 33:157–161.
134. Rosenthal VD, Guzman S, Crnich C. Device-associated nosocomial infection rates in intensive care units of Argentina. *Infection Control and Hospital Epidemiology*, 2004, 25:251–255.
135. Rosenthal VD, Guzman S, Orellano PW. Nosocomial infections in medical-surgical intensive care units in Argentina: attributable mortality and length of stay. *American Journal of Infection Control*, 2003, 31:291–295.
136. Rosenthal VD, Guzman S, Crnich C. Impact of an infection control program on rates of ventilator-associated pneumonia in intensive care units in 2 Argentinean hospitals. *American Journal of Infection Control*, 2006, 34:58–63.
137. Salomao R et al. Device-associated infection rates in intensive care units of Brazilian hospitals: findings of the International Nosocomial Infection Control Consortium. *Revista Panamericana de Salud Pública*, 2008, 24:195–202.
138. Moreno CA et al. Device-associated infection rate and mortality in intensive care units of 9 Colombian hospitals: findings of the International Nosocomial Infection Control Consortium. *Infection Control and Hospital Epidemiology*, 2006, 27:349–356.
139. Mehta A et al. Device-associated nosocomial infection rates in intensive care units of seven Indian cities. Findings of the International Nosocomial Infection Control Consortium (INICC). *Journal of Hospital Infection*, 2007, 67:168–174.
140. Askarian M, Williams C, Assadian O. Nosocomial infection rates following cardiothoracic surgery in Iran. *International Journal of Infectious Diseases*, 2006, 10:185–187.
141. Ramirez Barba EJ et al. Device-associated nosocomial infection rates in intensive care units in four Mexican public hospitals. *American Journal of Infection Control*, 2006, 34:244–247.
142. de Leon-Rosales SP et al. Prevalence of infections in intensive care units in Mexico: a multicenter study. *Critical Care Medicine*, 2000, 28:1316–1321.
143. Higuera F et al. Attributable cost and length of stay for patients with central venous catheter-associated bloodstream infection in Mexico City intensive care units: a prospective, matched analysis. *Infection Control and Hospital Epidemiology*, 2007, 28:31–35.
144. Cuellar LE et al. Device-associated infection rates and mortality in intensive care units of Peruvian hospitals: findings of the International Nosocomial Infection Control Consortium. *Revista Panamericana de Salud Pública*, 2008, 24:16–24.
145. Wojkowska-Mach J et al. Hospital-acquired pneumonia in the intensive care units of Polish hospitals. *Infection Control and Hospital Epidemiology*, 2006, 27:784–786.
146. Danchaivijitr S et al. Effect of an education program on the prevention of ventilator-associated pneumonia: a multicenter study. *Journal of the Medical Association of Thailand*, 2005, 88(Suppl. 10):S36–S41.
147. Leblebicioglu H et al. Device-associated hospital-acquired infection rates in Turkish intensive care units. Findings of the International Nosocomial Infection Control Consortium (INICC). *Journal of Hospital Infection*, 2007, 65:251–257.
148. Esen S, Leblebicioglu H. Prevalence of nosocomial infections at intensive care units in Turkey: a multicentre 1-day point prevalence study. *Scandinavian Journal of Infectious Diseases*, 2004, 36:144–148.
149. Azzam R, Dramaix M. A one-day prevalence survey of hospital-acquired infections in Lebanon. *Journal of Hospital Infection*, 2001, 49:74–78.
150. Pishori T, Siddiqui AR, Ahmed M. Surgical wound infection surveillance in general surgery procedures at a teaching hospital in Pakistan. *American Journal of Infection Control*, 2003, 31:296–301.
151. Brown S et al. Prevalence and predictors of surgical site infection in Tbilisi, Republic of Georgia. *Journal of Hospital Infection*, 2007, 66:160–166.
152. Brown SM et al. Prospective surveillance for surgical site infection in St. Petersburg, Russian Federation. *Infection Control and Hospital Epidemiology*, 2007, 28:319–325.
153. Kasatpibal N, Jamulitrat S, Chongsuvivatwong V. Standardized incidence rates of surgical site infection: a multicenter study in Thailand. *American Journal of Infection Control*, 2005, 33:587–594.
154. Kasatpibal N et al. Impact of surgeon-specific feedback on surgical site infection rates in Thailand. *Journal of Hospital Infection*, 2006, 63:148–155.
155. Yalcin AN et al. Postoperative wound infections. *Journal of Hospital Infection*, 1995, 29:305–309.
156. Nguyen D et al. Incidence and predictors of surgical-site infections in Vietnam. *Infection Control and Hospital Epidemiology*, 2001, 22:485–492.
157. Ider BE et al. Prevalence of hospital-acquired infections and antibiotic use in two tertiary Mongolian hospitals. *Journal of Hospital Infection*, 2010, 75:214–219.
158. Rosenthal VD et al. International Nosocomial Infection Control Consortium (INICC) report, data summary for 2003–2008, issued June 2009. *American Journal of Infection Control*, 2010, 38:95–104 e2.

159. Gopal Katherason S et al. Ventilator-associated nosocomial pneumonia in intensive care units in Malaysia. *Journal of Infection in Developing Countries*, 2009, 3:704–710.
160. Mesiano ER, Merchan-Hamann E. Bloodstream infections among patients using central venous catheters in intensive care units. *Revista Latino-Americana Enfermagem*, 2007, 15:453–459.
161. Gopal Katherason S et al. Baseline assessment of intensive care-acquired nosocomial infection surveillance in three adult intensive care units in Malaysia. *Journal of Infection in Developing Countries*, 2008, 2:364–368.
162. Rosenthal VD et al. Effect of an infection control program using education and performance feedback on rates of intravascular device-associated bloodstream infections in intensive care units in Argentina. *American Journal of Infection Control*, 2003, 31:405–409.
163. Starling CE, Couto BR, Pinheiro SM. Applying the Centers for Disease Control and Prevention and National Nosocomial Infection Control system methods in Brazilian hospitals. *American Journal of Infection Control*, 1997, 25:303–311.
164. Rezende EM, Couto BR, Starling CE, Modena CM. Prevalence of nosocomial infections in general hospitals in Belo Horizonte. *Infection Control and Hospital Epidemiology*, 1998, 19:872–876.
165. de Oliveira AC et al. Surgical site infection in patients submitted to digestive surgery: risk prediction and the NNIS risk index. *American Journal of Infection Control*, 2006, 34:201–207.
166. Duerink DO et al. Surveillance of healthcare-associated infections in Indonesian hospitals. *Journal of Hospital Infection*, 2006, 62:219–229.
167. Lahsaeizadeh S, Jafari H, Askarian M. Healthcare-associated infection in Shiraz, Iran 2004–2005. *Journal of Hospital Infection*, 2008, 69:283–287.
168. Arabshahi KS, Koohpayezade J. Investigation of risk factors for surgical wound infection among teaching hospitals in Tehran. *International Wound Journal*, 2006, 3:59–62.
169. Dumpis U et al. Prevalence of nosocomial infections in two Latvian hospitals. *Euro Surveillance*, 2003, 8:73–78.
170. Rosenthal VD et al. Device-associated nosocomial infections in 55 intensive care units of 8 developing countries. *Annals of Internal Medicine*, 2006, 145:582–591.
171. Rosenthal VD et al. International Nosocomial Infection Control Consortium report, data summary for 2002–2007, issued January 2008. *American Journal of Infection Control*, 2008, 36:627–637.
172. Rosenthal VD. Device-associated nosocomial infections in limited-resources countries: findings of the International Nosocomial Infection Control Consortium (INICC). *American Journal of Infection Control*, 2008, 36:S171. e7–12.
173. Rosenthal VD et al. Impact of International Nosocomial Infection Control Consortium (INICC) strategy on central line-associated bloodstream infection rates in the intensive care units of 15 developing countries. *Infection Control and Hospital Epidemiology*, 2010, 31:1264–1272.
174. Dogru A et al. The rate of device-associated nosocomial infections in a medical surgical intensive care unit of a training and research hospital in Turkey: one-year outcomes. *Japanese Journal of Infectious Diseases*, 2010, 63:95–98.
175. Madani N et al. Health-care associated infections rates, length of stay, and bacterial resistance in an intensive care unit of Morocco: findings of the International Nosocomial Infection Control Consortium (INICC). *International Archives of Medicine*, 2009, 2:29.
176. Faria S et al. The first prevalence survey of nosocomial infections in the university hospital centre 'Mother Teresa' of Tirana, Albania. *Journal of Hospital Infection*, 2007, 65:244–250.
177. Ribas RM, Gontijo Filho PP. Comparing hospital infections in the elderly versus younger adults: an experience in a Brazilian University Hospital. *Brazilian Journal of Infectious Diseases*, 2003, 7:210–215.
178. Raka L et al. Prevalence of nosocomial infections in high-risk units in the university clinical center of Kosova. *Infection Control and Hospital Epidemiology*, 2006, 27:421–423.
179. Valinteliene R, Jurkuvenas V, Jepsen OB. Prevalence of hospital-acquired infection in a Lithuanian hospital. *Journal of Hospital Infection*, 1996, 34:321–329.
180. Hughes AJ et al. Prevalence of nosocomial infection and antibiotic use at a university medical center in Malaysia. *Infection Control and Hospital Epidemiology*, 2005, 26:100–104.
181. Jroundi I et al. Prevalence of hospital-acquired infection in a Moroccan university hospital. *American Journal of Infection Control*, 2007, 35:412–416.
182. El Rhazi K et al. [Prévalence et facteurs de risque des infections nosocomiales au CHU Hassan II de Fès (Maroc).] *La Revue de Santé de la Méditerranée orientale*, 2007, 13:56–63.
183. Gosling R et al. Prevalence of hospital-acquired infections in a tertiary referral hospital in northern Tanzania. *Annals of Tropical Medicine and Parasitology*, 2003, 97:69–73.
184. Kallel H et al. Prevalence of hospital-acquired infection in a Tunisian hospital. *Journal of Hospital Infection*, 2005, 59:343–347.
185. Dridi E, Chetoui A, Zaoui A. [Investigation of the prevalence of nosocomial infection in a Tunisian regional hospital]. *Sanée Publique*, 2006, 18:187–194.
186. Metintas S et al. Prevalence and characteristics of nosocomial infections in a Turkish university hospital. *American Journal of Infection Control*, 2004, 32:409–413.
187. Allegranzi B et al. Successful implementation of the World Health Organization hand hygiene improvement strategy in a referral hospital in Mali, Africa. *Infection Control and Hospital Epidemiology*, 2010, 31:133–141.
188. Newman MJ. Nosocomial and community acquired infections in Korle Bu Teaching Hospital, Accra. *West African Journal of Medicine*, 2009, 28:300–303.
189. Velasco E et al. Nosocomial infections in an oncology intensive care unit. *American Journal of Infection Control*, 1997, 25:458–462.
190. Habibi S, et al. Epidemiology of nosocomial infections in medicine intensive care unit at a tertiary care hospital in northern India. *Tropical Doctor*, 2008, 38:233–235.
191. Khuri-Bulos NA et al. Nosocomial infections in the intensive care units at a university hospital in a developing country: comparison with National Nosocomial Infection Control intensive care unit rates. *American Journal of Infection Control*, 1999, 27:547–552.
192. Inan D et al. Device-associated nosocomial infection rates in Turkish medical-surgical intensive care units. *Infection Control and Hospital Epidemiology*, 2006, 27:343–348.
193. Meric M et al. Intensive care unit-acquired infections: incidence, risk factors and associated mortality in a Turkish university hospital. *Japanese Journal of Infectious Diseases*, 2005, 58:297–302.
194. Erbay H et al. Nosocomial infections in intensive care unit in a Turkish university hospital: a 2-year survey. *Intensive Care Medicine*, 2003, 29:1482–1488.
195. Chen YY et al. Incidence rate and variable cost of nosocomial infections in different types of intensive care units. *Infection Control and Hospital Epidemiology*, 2009, 30:39–46.
196. Rosenthal VD, Guzman S, Safdar N. Reduction in nosocomial infection with improved hand hygiene in intensive care units of a tertiary care hospital in Argentina. *American Journal of Infection Control*, 2005, 33:392–397.
197. Thongpiyapoom S et al. Device-associated infections and patterns of antimicrobial resistance in a medical-surgical intensive care unit in a university hospital in Thailand. *Journal of the Medical Association of Thailand*, 2004, 87:819–824.
198. Turgut H et al. Evaluation of device associated infection rates in intensive care units of Pamukkale University Hospital. *Infection*, 2008, 36:262–265.
199. Higuera F et al. The effect of process control on the incidence of central venous catheter-associated bloodstream infections and mortality in intensive care units in Mexico. *Critical Care Medicine*, 2005, 33:2022–2027.

200. Lobo RD et al. Impact of an educational program and policy changes on decreasing catheter-associated bloodstream infections in a medical intensive care unit in Brazil. *American Journal of Infection Control*, 2005, 33:83–87.
201. Rosenthal VD, Guzman S, Safdar N. Effect of education and performance feedback on rates of catheter-associated urinary tract infection in intensive care units in Argentina. *Infection Control and Hospital Epidemiology*, 2004, 25:47–50.
202. Simsek S et al. Ventilator-associated pneumonias in a cardiothoracic surgery centre postoperative intensive care unit. *Journal of Hospital Infection*, 2001, 47:321–324.
203. Erdem I et al. Incidence, etiology, and antibiotic resistance patterns of gram-negative microorganisms isolated from patients with ventilator-associated pneumonia in a medical-surgical intensive care unit of a teaching hospital in Istanbul, Turkey (2004–2006). *Japanese Journal of Infectious Diseases*, 2008, 61:339–342.
204. Osvaldo Iribarren B et al. [Factores de riesgo para mortalidad en neumonía asociada a ventilación mecánica.] *Revista Chilena de Infectología*, 2009, 26:227–232.
205. Zaidi AK et al. Hospital-acquired neonatal infections in developing countries. *Lancet*, 2005, 365:1175–1188.
206. Abramczyk ML et al. Nosocomial infection in a pediatric intensive care unit in a developing country. *Brazilian Journal of Infectious Diseases*, 2003, 7:375–380.
207. de Brito CS et al. Occurrence of bloodstream infection with different types of central vascular catheter in critically neonates. *Journal of Infection*, 2010, 60:128–132.
208. Nagata E, Brito AS, Matsuo T. Nosocomial infections in a neonatal intensive care unit: incidence and risk factors. *American Journal of Infection Control*, 2002, 30:26–31.
209. Cai XD et al. [Investigation of nosocomial infection in the neonatal intensive care unit]. *Zhongguo Dang Dai Er Ke Za Zhi [Chinese Journal of Contemporary Pediatrics]*, 2010, 12:81–84.
210. El-Nawawy AA et al. One year study of bacterial and fungal nosocomial infections among patients in pediatric intensive care unit (PICU) in Alexandria. *Journal of Tropical Pediatrics*, 2006, 52:185–191.
211. Asembergiene J et al. Nosocomial infections in the pediatric intensive care units in Lithuania. *Medicina (Kaunas)*, 2009, 45:29–36.
212. Gurskis V et al. Reduction of nosocomial infections and mortality attributable to nosocomial infections in pediatric intensive care units in Lithuania. *Medicina (Kaunas)*, 2009, 45:203–213.
213. Martinez-Aguilar G, Anaya-Arriaga MC, Avila-Figueroa C. [Incidence of nosocomial bacteremia and pneumonia in pediatric unit]. *Salud Pública de México*, 2001, 43:515–523.
214. Petdachai W. Ventilator-associated pneumonia in a newborn intensive care unit. *Southeast Asian Journal of Tropical Medicine and Public Health*, 2004, 35:724–729.
215. Petdachai W. Nosocomial pneumonia in a newborn intensive care unit. *Journal of the Medical Association of Thailand*, 2000, 83:392–397.
216. Ben Jaballah N et al. Epidemiology of hospital-acquired bloodstream infections in a Tunisian pediatric intensive care unit: a 2-year prospective study. *American Journal of Infection Control*, 2007, 35:613–618.
217. Koigi-Kamau R, Kabare LW, Wanyoike-Gichuhi J. Incidence of wound infection after caesarean delivery in a district hospital in central Kenya. *East African Medical Journal*, 2005, 82:357–361.
218. Raka L et al. Surgical site infections in an abdominal surgical ward at Kosovo Teaching Hospital. *Journal of Infection in Developing Countries*, 2007, 1:337–341.
219. Kanafani ZA et al. Surgical site infections following spinal surgery at a tertiary care center in Lebanon: incidence, microbiology, and risk factors. *Scandinavian Journal of Infectious Diseases*, 2006, 38:589–592.
220. Vilar-Compte D et al. Surgical site infections in ambulatory surgery: a 5-year experience. *American Journal of Infection Control*, 2001, 29:99–103.
221. Vilar-Compte D et al. Surgical site infections at the National Cancer Institute in Mexico: a case-control study. *American Journal of Infection Control*, 2000, 28:14–20.
222. Vilar-Compte D et al. [Surveillance of surgical wound infections. 18-month experience in the Instituto Nacional de Cancerología.] *Salud Pública de México*, 1999, 41(Suppl. 1):S44–S50.
223. Chadli M et al. [Incidence of surgical wound infections a prospective study in the Rabat Mohammed V military hospital, Morocco.] *Médecine et Maladies Infectieuses*, 2005, 35:218–222.
224. Sangrasi AK et al. Surgical site infection rate and associated risk factors in elective general surgery at a public sector medical university in Pakistan. *International Wound Journal*, 2008, 5:74–78.
225. Hernandez K et al. Incidence of and risk factors for surgical-site infections in a Peruvian hospital. *Infection Control and Hospital Epidemiology*, 2005, 26:473–477.
226. Maksimovic J et al. Surgical site infections in orthopedic patients: prospective cohort study. *Croatian Medical Journal*, 2008, 49:58–65.
227. Fehr J et al. Risk factors for surgical site infection in a Tanzanian district hospital: a challenge for the traditional National Nosocomial Infections Surveillance system index. *Infection Control and Hospital Epidemiology*, 2006, 27:1401–1404.
228. Luksamijarulkul P et al. Nosocomial surgical site infection among Photharam Hospital patients with surgery: incidence, risk factors and development of risk screening form. *Journal of the Medical Association of Thailand*, 2006, 89:81–89.
229. Kehachindawat P et al. Incidence and time trend of surgical site infection in Ramathibodi Hospital during the years 2003–2005. *Journal of the Medical Association of Thailand*, 2007, 90:1356–1362.
230. Kasatpibal N et al. Extra charge and extra length of postoperative stay attributable to surgical site infection in six selected operations. *Journal of the Medical Association of Thailand*, 2005, 88:1083–1091.
231. Dhidah L et al. [The role of surgical wounds in nosocomial infections. Prevalence study at Sahloul university hospital.] *Tunis Medical*, 1998, 7:401–407.
232. Erman T et al. Risk factors for surgical site infections in neurosurgery patients with antibiotic prophylaxis. *Surgical Neurology*, 2005, 63:107–112.
233. Kaya E et al. Risk factors for and effect of a one-year surveillance program on surgical site infection at a university hospital in Turkey. *Surgical Infection (Larchmont)*, 2006, 7:519–526.
234. Hodges AM, Agaba S. Wound infection in a rural hospital: the benefit of a wound management protocol. *Tropical Doctor*, 1997, 27:174–175.
235. Sohn AH et al. Prevalence of surgical-site infections and patterns of antimicrobial use in a large tertiary-care hospital in Ho Chi Minh City, Vietnam. *Infection Control and Hospital Epidemiology*, 2002, 23:382–387.
236. Le TA et al. Reduction in surgical site infections in neurosurgical patients associated with a bedside hand hygiene program in Vietnam. *Infection Control and Hospital Epidemiology*, 2007, 28:583–588.
237. Le TA et al. Microbiology of surgical site infections and associated antimicrobial use among Vietnamese orthopedic and neurosurgical patients. *Infection Control and Hospital Epidemiology*, 2006, 27:855–862.
238. Thu LT et al. Incidence of surgical site infections and accompanying risk factors in Vietnamese orthopaedic patients. *Journal of Hospital Infection*, 2005, 60:360–367.
239. Ameh EA et al. Surgical site infection in children: prospective analysis of the burden and risk factors in a sub-Saharan African setting. *Surgical Infections*, 2008, 10:5.

240. Morhason-Bello IO et al. Determinants of post-caesarean wound infection at the University College Hospital, Ibadan, Nigeria. *Nigerian Journal of Clinical Practice*, 2009, 12:1–5.
241. Ghelase MS et al. [A study of the incidence and the specific risk factors for surgical site nosocomial infections.] *Chirurgia (Bucur)*, 2009, 104:41–47.
242. Duque-Estrada EO et al. Wound infections in pediatric surgery: a study of 575 patients in a university hospital. *Pediatric Surgery International*, 2003, 19:436–438.
243. Sanchez-Arenas R et al. [Incidence of nosocomial surgical-site infections. Application of National Nosocomial Infections Surveillance System (NNIS) index and description of clinical and biochemical features from patients undergoing first-time ventriculoperitoneal shunt.] *Cirugia y Cirujanos*, 2009, 77:13–19.
244. Garcia HJ et al. [Risk factors for surgical site infections in newborns in a neonatal intensive care unit.] *Revista de Investigación Clínica*, 2005, 57:425–433.
245. Kesah CN et al. Aerobic bacterial nosocomial infections in paediatric surgical patients at a tertiary health institution in Lagos, Nigeria. *Nigerian Postgraduate Medical Journal*, 2004, 11:4–9.
246. Okeke IN et al. Antimicrobial resistance in developing countries. Part I: recent trends and current status. *Lancet Infectious Diseases*, 2005, 5:481–493.
247. Soufir L et al. Attributable morbidity and mortality of catheter-related septicemia in critically ill patients: a matched, risk-adjusted, cohort study. *Infection Control and Hospital Epidemiology*, 1999, 20:396–401.
248. Vincent JL et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) study. EPIC International Advisory Committee. *Journal of the American Medical Association*, 1995, 274:639–644.
249. Hugonnet S et al. Impact of ventilator-associated pneumonia on resource utilization and patient outcome. *Infection Control and Hospital Epidemiology*, 2004, 25:1090–1096.
250. Safdar N et al. Clinical and economic consequences of ventilator-associated pneumonia: a systematic review. *Critical Care Medicine*, 2005, 33:2184–2193.
251. O'Grady NP et al. Guidelines for the prevention of intravascular catheter-related infections. Centers for Disease Control and Prevention. *Morbidity and Mortality Weekly Report*, 2002, 51(RR-10):1–29.
252. Tacconelli E et al. Epidemiology, medical outcomes and costs of catheter-related bloodstream infections in intensive care units of four European countries: literature- and registry-based estimates. *Journal of Hospital Infection*, 2009, 72:97–103.
253. Cavalcante SS et al. Risk factors for developing nosocomial infections among pediatric patients. *Pediatric Infectious Diseases Journal*, 2006, 25:438–445.
254. Contreras-Cuellar GA et al. Device-associated infections in a Colombian neonatal intensive care unit. *Revista de Salud Pública (Bogota)*, 2007, 9:439–447.
255. Lakshmi KS et al. Study of nosocomial primary bloodstream infections in a pediatric intensive care unit. *Journal of Tropical Pediatrics*, 2007, 53:87–92.
256. Juarez-Munoz IE et al. [The costs of hospital infections in a group of patients in a tertiary-care hospital.] *Gaceta Médica México*, 1999, 135:457–462.
257. Navarrete-Navarro S, Armengol-Sanchez G. [Secondary costs due to nosocomial infections in 2 pediatric intensive care units.] *Salud Pública de México*, 1999, 41(Suppl. 1):S51–S58.
258. Perez-Gonzalez LF, Ruiz-Gonzalez JM, Noyola DE. Nosocomial bacteremia in children: a 15-year experience at a general hospital in Mexico. *Infection Control and Hospital Epidemiology*, 2007, 28:418–422.
259. Porras-Hernandez JD et al. A prospective study of surgical site infections in a pediatric hospital in Mexico City. *American Journal of Infection Control*, 2003, 31:302–308.
260. Onen A et al. Epidemiology and control of nosocomial infections in paediatric surgery. *Journal of Hospital Infection*, 2002, 52:166–170.
261. Soares de Macedo JL, Santos JB. Nosocomial infections in a Brazilian Burn Unit. *Burns*, 2006, 32:477–481.
262. Giamberardino HI et al. Risk factors for nosocomial infection in trauma patients. *Brazilian Journal of Infectious Diseases*, 2007, 11:285–289.
263. Toufen C, Jr. Prevalence rates of infection in intensive care units of a tertiary teaching hospital. *Revista do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo*, 2003, 58:254–259.
264. Santos KR et al. Surgical site infection: rates, etiology and resistance patterns to antimicrobials among strains isolated at Rio de Janeiro University Hospital. *Infection*, 1997, 25:217–220.
265. Boas PJ, Ruiz T. [Occurrence of hospital infection among interned elderly in a university hospital.] *Revista de Saúde Pública*, 2004, 38:372–378.
266. Jaimes F et al. Incidence and risk factors for ventilator-associated pneumonia in a developing country: where is the difference? *Respiratory Medicine*, 2007, 101:762–767.
267. Agarwal R et al. Epidemiology, risk factors and outcome of nosocomial infections in a respiratory intensive care unit in North India. *Journal of Infection*, 2006, 53:98–105.
268. Merchant M, Karnad DR, Kanbur AA. Incidence of nosocomial pneumonia in a medical intensive care unit and general medical ward patients in a public hospital in Bombay, India. *Journal of Hospital Infection*, 1998, 39:143–148.
269. Pawar M et al. Central venous catheter-related blood stream infections: incidence, risk factors, outcome, and associated pathogens. *Journal of Cardiothoracic and Vascular Anesthesia*, 2004, 18:304–308.
270. Mukhopadhyay C, Bhargava A, Ayyagari A. Role of mechanical ventilation & development of multidrug resistant organisms in hospital acquired pneumonia. *Indian Journal of Medical Research*, 2003, 118:229–235.
271. Pawar M et al. Ventilator-associated pneumonia: Incidence, risk factors, outcome, and microbiology. *Journal of Cardiothoracic and Vascular Anesthesia*, 2003, 17:22–28.
272. Bhatia JY et al. Postoperative wound infection in patients undergoing coronary artery bypass graft surgery: a prospective study with evaluation of risk factors. *Indian Journal of Medical Microbiology*, 2003, 21:246–251.
273. Kothari A et al. Costs associated with hospital-acquired bacteraemia in an Indian hospital: a case-control study. *Journal of Hospital Infection*, 2009, 71:143–148.
274. Askarian M, Gooran NR. National nosocomial infection surveillance system-based study in Iran: additional hospital stay attributable to nosocomial infections. *American Journal of Infection Control*, 2003, 31:465–468.
275. Askarian M et al. Incidence and outcome of nosocomial infections in female burn patients in Shiraz, Iran. *American Journal of Infection Control*, 2004, 32:23–26.
276. Kanafani ZA et al. Ventilator-associated pneumonia at a tertiary-care center in a developing country: incidence, microbiology, and susceptibility patterns of isolated microorganisms. *Infection Control and Hospital Epidemiology*, 2003, 24:864–869.
277. Vosylius S, Sipylaitis J, Ivaskevicius J. Intensive care unit acquired infection: a prevalence and impact on morbidity and mortality. *Acta Anaesthesiologica Scandinavica*, 2003, 47:1132–1137.
278. Rozaidi SW, Sukro J, Dan A. The incidence of nosocomial infection in the intensive care unit, hospital universiti Kebangsaan Malaysia: ICU-acquired nosocomial infection surveillance program 1998-1999. *Medical Journal of Malaysia*, 2001, 56:207–222.
279. Sanchez-Velazquez LD, Ponce de Leon Rosales S, Rangel Frausto MS. The burden of nosocomial infection in the intensive care unit: effects on organ failure, mortality and costs. A nested case-control study. *Archives of Medical Research*, 2006, 37:370–375.

280. Thanamee N, Sujaritjan N, Techasena W. Pneumonia in mechanically ventilated patients in Nan hospital intensive care unit. *Journal of the Medical Association of Thailand*, 1995, 78(Suppl. 2):S102–S104.
281. Elatrous S et al. Incidence and risk factors of ventilator-associated pneumonia: a one-year prospective survey. *Clinical Intensive Care*, 1996, 7:276–281.
282. Oncul O et al. The evaluation of nosocomial infection during 1-year-period in the burn unit of a training hospital in Istanbul, Turkey. *Burns*, 2002, 28:738–744.
283. Esatoglu AE et al. Additional cost of hospital-acquired infection to the patient: a case study in Turkey. *Health Services Management Research*, 2006, 19:137–143.
284. Inan D et al. Daily antibiotic cost of nosocomial infections in a Turkish university hospital. *BMC Infectious Diseases*, 2005, 5:5.
285. Erbay RH et al. Costs and risk factors for ventilator-associated pneumonia in a Turkish university hospital's intensive care unit: a case-control study. *BMC Pulmonary Medicine*, 2004, 4:3.
286. Ertugrul BM et al. Ventilator-associated pneumonia in surgical emergency intensive care unit. *Saudi Medical Journal*, 2006, 27:52–57.
287. Gol MK et al. Bloodstream, respiratory, and deep surgical wound infections after open heart surgery. *Journal of Cardiac Surgery*, 1998, 13:252–259.
288. Khan MM, Celik Y. Cost of nosocomial infection in Turkey: an estimate based on the university hospital data. *Health Services Management Research*, 2001, 14:49–54.
289. Zhang Q et al. Health-associated infections in a pediatric nephrology unit in China. *American Journal of Infection Control*, 2010, 38:473–475.
290. de Oliveira AC, Kovner CT, da Silva RS. Nosocomial infection in an intensive care unit in a Brazilian university hospital. *Revista Latino-Americana Enfermagem*, 2010, 18:233–239.
291. Joseph NM et al. Ventilator-associated pneumonia in a tertiary care hospital in India: role of multi-drug resistant pathogens. *Journal of Infection in Developing Countries*, 2010, 4:218–225.
292. Rodrigues PM et al. Ventilator-associated pneumonia: epidemiology and impact on the clinical evolution of ICU patients. *Jornal Brasileiro de Pneumologia*, 2009, 35:1084–1091.
293. Apisarnthanarak A et al. Effectiveness of an educational program to reduce ventilator-associated pneumonia in a tertiary care center in Thailand: a 4-year study. *Clinical Infectious Diseases*, 2007, 45:704–711.
294. Rosenthal VD et al. The attributable cost, length of hospital stay, and mortality of central line-associated bloodstream infection in intensive care departments in Argentina: a prospective, matched analysis. *American Journal of Infection Control*, 2003, 31:475–480.
295. Pittet D et al. Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. *Lancet*, 2000, 356:1307–1312.
296. Eggimann P et al. Impact of a prevention strategy targeted at vascular-access care on incidence of infections acquired in intensive care. *Lancet*, 2000, 355:1864–1868.
297. Pronovost P et al. An intervention to decrease catheter-related bloodstream infections in the ICU. *New England Journal of Medicine*, 2006, 355:2725–2732.
298. Kollef M. SMART approaches for reducing nosocomial infections in the ICU. *Chest*, 2008, 134:447–456.
299. WHO Guidelines on Hand Hygiene in Health Care. Geneva: World Health Organization, 2009.
300. Tablan OC et al. Guidelines for preventing health-care--associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. *Morbidity and Mortality Weekly Report*, 2004, 53(RR-3):1–36.
301. *Practical guidelines for infection control in health care facilities*. Geneva, World Health Organization/Western Pacific Regional Office/South-East Asia Regional Office, 2004.
302. Anderson DJ et al. Strategies to prevent surgical site infections in acute care hospitals. *Infection Control and Hospital Epidemiology*, 2008, 29(Suppl. 1):S51–S61.
303. Coffin SE et al. Strategies to prevent ventilator-associated pneumonia in acute care hospitals. *Infection Control and Hospital Epidemiology*, 2008, 29(Suppl. 1):S31–S40.
304. Gould CV et al. Guideline for prevention of catheter-associated urinary tract infections 2009. *Infection Control and Hospital Epidemiology*, 2010, 31:319–326.
305. Siegel JD et al. Guidelines for isolation precautions: preventing transmission of infectious agents in healthcare settings 2007. *American Journal of Infection Control*, 2007, 35 (Suppl 10):S65–S164.
306. Picheansathian W, Pearson A, Suchaxaya P. The effectiveness of a promotion programme on hand hygiene compliance and nosocomial infections in a neonatal intensive care unit. *International Journal of Nursing Practice*, 2008, 14:315–321.
307. Caniza MA et al. A practical guide to alcohol-based hand hygiene infrastructure in a resource-poor pediatric hospital. *American Journal of Infection Control*, 2009, 37:851–854.
308. Bedat B et al. Successful hand hygiene improvement strategy in a referral children's hospital in Armenia. *Journal of Hospital Infection*, 2010, 76:362–363.
309. Nguyen KV, Nguyen PT, Jones SL. Effectiveness of an alcohol-based hand hygiene programme in reducing nosocomial infections in the urology ward of Binh Dan hospital, Vietnam. *Tropical Medicine & International Health*, 2008, 13:1297–1302.
310. *Core components for infection prevention and control programmes. Report of the second meeting informal network on infection prevention and control in health care*. Geneva, World Health Organization, 2009.
311. *Essential environmental health standards in health care*. Geneva, World Health Organization, 2008.
312. Sehulster LM et al. *Guidelines for environmental infection control in health-care facilities. Recommendations from CDC and the Healthcare Infection Control Practices Advisory Committee (HICPAC)*. Chicago, IL, American Society for Healthcare Engineering/American Hospital Association, 2004.
313. Rutala WA. *CDC guideline for disinfection and sterilization in healthcare facilities*. Atlanta, GA, Centers for Disease Prevention and Control, 2008.
314. Acosta-Gnass SI, de Andrade Stempluk V. *Sterilization manual for health centers*. Washington, DC, Pan American Health Organization, World Health Organization, 2009:1–167.
315. *WHO best practices for injections and related procedures toolkit*. Geneva, World Health Organization, 2010.
316. *Waste management publications*. Geneva, World Health Organization. (http://www.who.int/immunization_safety/publications/waste_management/ISPPpublicationsWM/en/index.html; accessed 13 April 2011.)
317. Siegel JD et al. Management of multidrug-resistant organisms in health care settings, 2006. *American Journal of Infection Control*, 2007, 35(Suppl. 2):S165–193.
318. *Joint WHO-ILO-UNAIDS policy guidelines for improving health worker access to HIV and TB prevention, treatment, care and support services*. Geneva, World Health Organization, 2010.
319. *WHO patient safety curriculum guide for medical schools*. Geneva, World Health Organization, 2009.
320. *WHO patient safety curriculum guide: multi-professional edition*. Geneva, World Health Organization, 2011.
321. Longtin Y et al. Patient participation: current knowledge and applicability to patient safety. *Mayo Clinic Proceedings*, 2010, 85:53–62.

APPENDIX

Search terms

Cross-infection [MeSH Term], nosocomial infection, nosocomial infections, hospital acquired infection, hospital acquired infections, hospital-acquired infection, hospital-acquired infections, health care associated infection, health care associated infections, health care-associated infection, health care-associated infections, and infection control [Mesh Term], infection control, bloodstream infection, bloodstream infections, nosocomial bacteremia, nosocomial bacteraemia, nosocomial septicemia, nosocomial septicaemia, device-associated infection, device-associated infections, urinary tract infection, urinary tract infections, surgical site infection, surgical site infections, wound infection, wound infections, ventilator-associated pneumonia, ventilator associated pneumonia, hospital-acquired pneumonia, hospital acquired pneumonia, developing country, developing countries, and developing countries [Mesh Terms], developed country, developed countries, and developed countries [Mesh Terms] and names of the countries individually.

WHO regional medical databases

Western Pacific Region Index Medicus (WPRIM); Latin America and Caribbean Health Sciences (LILACS); African Index Medicus (AIM); Index Medicus for the Eastern Mediterranean Region Database (IMEMR); Index Medicus for the South-East Asian Region (IMSEAR-HELLIS).



**World Health
Organization**

Patient Safety

A World Alliance for Safer Health Care

World Health Organization

20 Avenue Appia
CH – 1211 Geneva 27
Switzerland
Tel: +41 (0) 22 791 50 60

Email

savelives@who.int

Please visit us at:

www.who.int/patientsafety/en/
www.who.int/gpsc/en

